

AML in Older Adults Supplement 2: Disclosure of Interests Forms of Panelists

Gregory Abel

Shabbir Alibhai

Jessica Altman

Romina Brignardello-Petersen

Rena Buckstein

Hannah Choe

Pinkal Desai

Harry Erba

Gordon Guyatt

Christopher Hourigan

Thomas LeBlanc

Mark Litzow

Janet MacEachern

Laura Michaelis

Sudipto Mukherjee

Kristen O'Dwyer

Ashley Rosko

Mikkael Sekeres

Richard Stone



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made? **I co-authored a review to be published in *Blood* as part of its 2018 series Hematologic Disease at Older Age entitled "Frailty and the management of hematologic malignancies" which does discuss some approaches for older patients with AML.**

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain: **I see patients with AML in clinic and on the wards, and my institution does charge patients for their visits.**

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I am not sure, but it is important that it be clear in any resulting manuscripts that the opinions in the guidelines I endorse are my own after reviewing the data and not that of my institution (Dana-Farber).

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
 Yes

If yes, what is your primary specialty or subspecialty?

Hematologic oncology, especially older patients with MDS and leukemia.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
 Yes

If yes, please explain: **I see and treat older patients with MDS and leukemia, so these guidelines will be applicable to some of my patients.**

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
 Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	<p>I am listed as a Co-I (not Co-PI or site PI) on many studies at DFCI for patients with blood cancers, including some for AML.</p> <p>I do not receive any financial compensation for these studies, either for my salary or for resources for my own research program. I am not involved in the day-to-day running of these studies.</p> <p>The reason I am listed is in case I am on-service and one of the PIs is away, I can potentially be of help. This has never happened.</p>	7/16/2019	Not a COI.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/1/2017; Kunkle 12/29/17	No	No	Dr. Abel has no current financial conflicts of interest with for-profit companies that could be affected by these guidelines.
Alexander 10/25/2018	No	No	On 10/24/2018, Dr. Abel confirmed all information in this form.
Alexander 5/20/2019	No	No	On 04/16/2019, Dr. Abel confirmed all information in this form.
Alexander 7/15/2019	No	No	New disclosure. See Part D.
Alexander 1/10/2020	No	No	On 1/10/2020, Dr. Abel confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Abel reports previously published opinions about the treatment of older adults with AML. As a hematologist/oncologist specialist, he also sees and treats patients with MDS and leukemia.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in older adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I have published research looking at quality of life and functional status in older adults with AML who underwent intensive chemotherapy. These were published in *Leukemia Research*, *Critical Reviews in Oncology and Hematology*, and the *Journal of Geriatric Oncology*. I have also published a study looking at the referral patterns and treatment of older adults with AML in Cancer using large administrative data in Ontario, Canada. In those papers I advocated for greater use of intensive chemotherapy in relatively fit older adults with AML, and for referral to centres of excellence for an opinion for most older adults diagnosed with AML to reduce undertreatment.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

My institution is a referral centre for AML in the Greater Toronto Area (GTA, catchment area 5 million), and may stand to benefit from more referrals if this is advocated by the guidelines. However, we already are the referral centre for the vast majority (estimates of >85%) of the GTA AML patients, so impact would be small.

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

No impact whatsoever

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Geriatric Oncology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

There is a possibility that geriatric assessment may be recommended in some older adults with AML. I am the lead for my hospital's geriatric oncology clinic and theoretically we may benefit from seeing more AML patients.

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Astellas	In Spring 2018 I participated in a panel to create a guideline for the management of cancer-related fatigue in patients. my expertise was related to geriatric oncology and exercise science. I was paid an honorarium by Astellas. There was no connection to AML.	10/19/2018	Indirect COI. Astellas markets gilterinib for treatment of relapsed or refractory AML. Relapsed or refractory AML is not in the scope of these guidelines, but Astellas could be indirectly affected by recommendations made by the panel.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH guideline panel on acute myeloid leukemia in older adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/4/2017; Kunkle, 12/29/17	No	No	Dr. Alibhai does not have any current financial conflicts of interest with for-profit companies that could be affected by these guidelines.
Alexander 4/12/2019	No	Yes	New disclosures. See Part D. Dr. Alibhai disclosed a direct financial relationship with Astellas, which may be indirectly affected by the guidelines.
Alexander 5/20/2019	No	Yes	On 4/16/2019, Dr. Alibhai confirmed all information in this form.
Alexander 1/10/2020	No	Yes	On 1/10/2020, Dr. Alibhai confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Alibhai reports that he has published opinions advocating for greater use of intensive chemotherapy in relatively fit older adults with AML and for referral of older adults with AML to centers of excellence. Dr. Alibhai is a geriatric oncologist who directs the geriatric oncology clinic for such a center.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Astellas	Advisory Board	9/29/2017	Not a COI. Astellas is developing gilteritinib in Phase III clinical trials for treatment of AML. However, this paid activity ended before Dr. Altman's appointment to the guideline panel.
Novartis	Advisory Board	6/2/2017	Not a COI. Novartis markets midostaurin (Rydapt) for treatment of AML. However, this paid activity ended before Dr. Altman's appointment to the guideline panel.
Celgene	Advisory Board	12/16/2016	Not a COI. Celgene markets enasidenib and azacitidine for treatment of AML. However, this paid activity ended before Dr. Altman's appointment to the guideline panel.
Immune Pharmaceuticals	Advisory Board	12/4/2016	Not a COI. Immune Pharmaceuticals markets histamine dihydrochloride (Celpene) (approved in EU) for maintenance of first remission in patients with AML. However, this paid activity ended before Dr. Altman's appointment to the guideline panel.
Syros	Advisory Board	6/3/2016	Not a COI. Syros is developing SY-1425 in phase II clinical trial for treatment of newly diagnosed, relapsed or refractory AML. However, this paid activity ended before Dr. Altman's appointment to the guideline panel.
BMS	Advisory Board	3/21/2016	Not a COI. BMS is developing nivolumab in phase II clinical trial for treatment of AML. However, this paid activity ended before Dr. Altman's appointment to the guideline panel.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Astellas	Advisory Board (not paid)	3/19/2016	Not a COI. Astellas is developing gilteritinib in Phase III clinical trials for treatment of AML. However, this paid activity ended before Dr. Altman's appointment to the guideline panel.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Genentech, MSK	Clinical Trial (NU MSK12H10)	PI	7/25/2016	Not a COI. As part of the Roche Group, Genentech markets Venclexta for treatment of AML. However, this clinical trial ended before Dr. Altman’s appointment to the guideline panel.
Agios Pharmaceuticals	Clinical Trial (DRUG AG120-C-001)	PI	4/26/2017	Not a COI. Agios is developing AG-221 for treatment of AML in phase III clinical trial. However, this clinical trial ended before Dr. Altman’s appointment to the guideline panel.
Agios Pharmaceuticals	Clinical Trial (DRUG AG221-C-001)	PI	5/27/2016	Not a COI. Agios is developing AG-221 for treatment of AML in phase III

Company	Description of Research	My Role	End Date	For ASH Internal Use
				clinical trial. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
Agios	Clinical Trial (DRUG AG881-C-001)	PI	12/16/2016	Not a COI. Agios is developing AG-221 for treatment of AML in phase III clinical trial. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
Boehringer Ingelheim	Clinical Trial (DRUG 1315-0001): Dose escalation in patients with refractory or relapsed acute myeloid leukemia and in patients in complete remission with high risk to relapse	Site PI	Current	Indirect COI. BI 836858 was granted orphan drug status for AML by the FDA in March 2017. BI is developing volasertib for treatment of AML in Phase III clinical trial. This research is relevant to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
Boehringer Ingelheim	Clinical Trial (DRUG 1315.2): An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in combination with decitabine in patients with AML	Site - PI	Current	Indirect COI. BI 836858 was granted orphan drug status for AML by the FDA in March 2017. BI is developing volasertib for treatment of AML in Phase III clinical trial. This research is relevant to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
Astellas	Clinical Trial (DRUG 2215-CL-0103): A Study of ASP2215 in combination with induction consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia	Site PI	Current	Indirect COI. Astellas is developing gilteritinib in phase III clinical trial and the subject of the research is relevant to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Celgene	Clinical Trial (DRUG CC-90009-AML-001): a dose-finding study of CC-90009 in subjects with relapsed or refractory acute myeloid leukemia	Site PI	Current	Indirect COI. Celgene markets enasidenib and azacitidine for treatment of AML and is developing luspatercept for treatment of AML in phase III clinical trial. The subject of the research is relevant to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
FUJIFILM Pharmaceuticals	Clinical Trial (DRUG FF-10101-US101-201): Study of FF-10101-01 in patients with relapsed on refractory AML	Site PI	Current	Indirect COI. FUJIFILM pharmaceuticals is developing FF 10101-01 for the treatment of AML in phase I clinical trial and the subject of the research is relevant to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
MedImmune, LLC	Clinical Trial (DRUG CD-ON-CAT-8015-1053)	Sub-I	6/21/2016	Not a COI. MedImmune is a member of the AstraZeneca group. AstraZeneca is developing AZD9150 and MEDI7247 for treatment of hematologic malignancies, including AML. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
Juno Therapeutics	Clinical Trial (DRUG 015001)	Sub-I	2/16/2016	Not a COI. Juno Therapeutics is studying the use of genetically modified T cells in patients with AML that have previously undergone bone marrow transplantation. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Juno Therapeutics	Clinical Trial (DRUG 015002)	Sub-I	3/31/2017	Not a COI. Juno Therapeutics studying the use of genetically modified T cells in patients with AML that have previously undergone bone marrow transplantation. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
BMS	Clinical Trial (NU 15H13): Nivolumab and dasatinib in treating patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia	Sub-I	Current	Very Indirect COI. Bristol Myers Squibb is developing nivolumab for treatment of AML in phase II clinical trial. However, the subject of the research is ALL, not AML, Dr. Altman does not have a leadership role and all funding goes to her institution.
Pfizer	Clinical Trial (NU17CU01): study of NU172 as anticoagulation in patients undergoing off-pump CABG surgery	Sub-I	Current	Very Indirect COI. Pfizer is developing glasdegib for treatment of AML in phase II clinical trial. However, the subject of the research is not relevant to the guideline topic, Dr. Altman does not have a leadership role, and all funding goes to her institution.
FORMA	Clinical Trial (DRUG 1101-HEM-101): Study of a novel BET inhibitor FT-1101 in patients with relapsed or refractory hematologic malignancies (AML, MDS)	Sub-I	Current	Indirect COI. FORMA is developing FT-1101 (a BET inhibitor) in Phase I clinical trial for treatment of AML. The subject of the research is relevant to the guideline topic. However, it is unlikely that BET inhibitors will be included in the scope of the guideline. FORMA may be indirectly affected by recommendations that the guideline panel makes about other treatment options. Furthermore, Dr. Altman

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				does not have a leadership role and all funding goes to her institution.
Ambit	Clinical Trial (DRUG AC220-007)	Sub-I	5/17/2016	Not a COI. Ambit Biosciences was acquired by Daiichi Sankyo. Daiichi Sankyo is developing quizartinib for treatment of AML in phase III clinical trial. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
FLX Bio, Inc.	Clinical Trial (DRUG FLX925-01)	Sub-I	4/11/2017	Not a COI. FLX Bio is developing FLX925 for treatment of AML in phase I clinical trial. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
Calithera Biosciences	Clinical Trial (DRUG CX-839-003)	Sub-I	10/25/2016	Not a COI. Calithera Biosciences is developing CB-839 for treatment of AML in phase II clinical trials. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
Cellerant Therapeutics	Clinical Trial (DRUG CLT008-03)	Sub-I	5/24/2017	Not a COI. Cellerant Therapeutics is developing CLT-008 for treatment of AML in phase II clinical trial. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
Celgene	Clinical Trial (DRUG AG-221-AML-004): An efficacy and safety study of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an	Sub-I	Current	Indirect COI. Celgene markets enasidenib and azacitidine for treatment of AML, and is developing luspatercept and CC-90007 for treatment of AML in phase III clinical trial. The subject of the research is relevant to the guideline topic. However, Dr. Altman

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	isocitrate dehydrogenase 2 mutation			does not have a leadership role and all funding goes to her institution.
Celgene	Clinical Trial (DRUG AG-221-AML-005): a safety and efficacy study of oral AG-120 plus subcutaneous azacitidine and oral AG-221 plus subcutaneous azacitidine in subjects with newly diagnosed AML	Sub-I	Current	Indirect COI. Celgene markets enasidenib and azacitidine for treatment of AML and is developing CC-900007 for treatment of AML in phase III clinical trial. The subject of the research is relevant to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
Millennium	Clinical Trial (DRUG C34002): safety, tolerability, and efficacy of TAK-659 in patients with relapsed on refractory acute myelogenous leukemia	Sub-I	Current	Indirect COI. Millennium Pharmaceuticals is also known as Takeda Oncology. Takeda is developing TAK-659 for treatment of AML in Phase II clinical trial. The subject of the research is relevant to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
Karyopharm Therapeutics	Clinical Trial (DRUG KCP-330-008): Selinexor (KPT-330) in Older Patients with Relapsed AML	Sub-I	12/8/2016	Not a COI. Karyopharm Therapeutics is developing selinexor for treatment of AML in relapsed older adults. However, this clinical trial ended before Dr. Altman's appointment to the guideline panel.
Abbvie	Clinical Trial (DRUG M14-358): Phase 1b acute myelogenous leukemia (aml) study with ABT-199 + decitabine or azacitidine (chemo combo)	Sub-I	6/26/2017	Not a COI. As part of the Roche group, Abbvie markets venetoclax for treatment of AML in elderly patients. Abbvie is also developing ibrutinib for treatment of AML in phase II clinical trial. However, this clinical trial ended before Dr. Altman's

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				appointment to the guideline panel.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Israel Cancer Research Fund (receives contributions from some pharmaceutical companies)	Board Member	Unpaid	Current	Not a COI. The Israel Cancer Research Fund is a not for profit organization and does not market any devices or drugs used in the diagnosis or treatment of AML.
The ARK	Board Member	Unpaid	Current	Not a COI. ARK is a not for profit organization and does not market any devices or drugs used in the diagnosis or treatment of AML. ARK provides basic medical care and food to families in need in Chicago.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
American Society of Hematology	Steering committee for AML Matters, an educational program on the diagnosis and treatment of AML hosted by the American Society of Hematology, The American Society for Clinical Pathology, National Marrow Donor Program, Oncology Nursing Society, and the France Foundation.	Paid	1/23/2017	Not a COI. The American Society of Hematology is a not for profit organization, and does not market any devices or drugs used in the diagnosis or treatment of AML.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in older adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I sit on the NCCN AML panel. Otherwise, I have not been involved with creating any guidelines in AML.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I believe that my institution would actively support me. The Cancer Center leadership will also be pleased that I am participating in this endeavor.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Hematology with specific interests in treating patients with AML, ALL, MDS, CML, and other myeloid neoplasms

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain: I am currently and will continue to prescribe agents that are approved for the treatment of AML. We also sometimes use agents off-label; when clinically appropriate. I am happy to provide any further information.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
France Foundation / American Society of Hematology	<p>Participation on steering committee that will create content for “CML Interactive Cases: An Immersive Simulated Learning Experience”.</p> <p>Participation includes a \$3500 honorarium paid by ASH/France Foundation.</p> <p>ASH/France Foundation is receiving support for this program through an unrestricted educational grant from Pfizer. Pfizer has no control over the content.</p>	1/4/2018	<p>No COI. This activity is supported by Pfizer, which markets treatments for AML. However, the activity meets ACCME criteria intended to prevent commercial influence over content, and the payment is made by ASH/France Foundation rather than Pfizer directly.</p>
Cancer Expert Now	<p>Direct payment for participation in anonymous panel discussion about AML. Cancer Expert Now received funding for this activity from an undisclosed sponsor. The identity of the sponsor was not disclosed to Dr. Altman, nor was her name disclosed to the sponsor.</p>	6/21/2018	<p>Not a COI. Cancer Expert Now seems to market physician education, patient referral services, and cancer-related resources for employers including guidance around cancer prevention and optimal care. None of these products or services will be directly addressed by the ASH guidelines. If additional information about the sponsor of this activity becomes available, this judgment (not a COI) could change.</p>

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Hemedicus, Inc / American Society of Hematology	Educational session: “Evolving Options in Acute Myeloid Leukemia Therapy”. This session was held at the ASH annual meeting. Hemedicus received support for this program through an educational grant from Agios. Agios had no control over the content.	12/13/2018	No COI. This activity is supported by Agios, which is developing treatments for AML. However, the activity meets ACCME criteria intended to prevent commercial influence over content, and the payment is made by ASH/Hemedicus rather than Agios directly.
Glycomimetics	Direct payment for participation on data safety and monitoring board	12/13/2018	Indirect COI. Glycomimetics is developing treatments for newly diagnosed AML in Phase II clinical trials, and treatments for relapsed/refractory AML in phase III clinical trials.
AbbVie	Direct payment for participation on an advisory board	4/13/2019	Direct COI. AbbVie markets venetoclax for treatment of AML in older adults with previously untreated AML.
Daiichi Sankyo	Direct payment for participation on an advisory board.	4/13/2019	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for treatment of newly diagnosed, relapse and refractory AML.
Theradex	Direct payment for participation on an advisory board	4/16/2019	Not a COI. Theradex provides oncology clinical trial services and does not market any drugs or devices used in the diagnosis or treatment of AML.
BioSight, LTD	A Phase 2b Open- Label, Single Arm, Multi-Center Study to	4/16/2019	Indirect COI. Biosight - is developing BST-236 in phase II clinical trials

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy. US lead and Sub-I at Northwestern University.		for treatment of AML and the subject of the research is related to the guideline topic. However, all funding goes to Dr. Altman's institution.
AbbVie / Astellas	Phase I trial of venetoclax + gilteritinib in relapsed/refractory FLT3 mutated AML. Sub PI.	4/16/2019	Indirect COI. AbbVie markets venetoclax for treatment of AML and Astellas markets gilteritinib for treatment of relapsed/refractory AML. The subject of the research is related to the guideline topic. However, all funding goes to Dr. Altman's institution and she does not have a leadership role.
Amphivena Therapeutics, Inc.	A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Sub PI	4/16/2019	Indirect COI. Amphivena is developing AMV564 in phase I clinical trials for treatment of AML. However, all funding goes to Dr. Altman's institution and she does not have a leadership role.
Phebra	Unpaid consulting on the development of oral arsenic trioxide.	4/16/2019	Not a COI. Phebra is not currently developing any drugs or devices used in the diagnosis or treatment of AML.
Northwestern University / Boehringer Ingelheim	NU 17H04 - phase Ib, open label, combination study of	6/26/2019	Indirect COI. BI 836858 was granted orphan drug status for AML by

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	Nintedanib with 5-azacitidine in newly diagnosed AML characterized by HOX gene over expression, that are not candidates for intensive chemotherapy. Boehringer Ingelheim provide the drug, all other aspects are paid for by Northwestern. PI.		the FDA in March 2017. BI is developing volasertib for treatment of AML in Phase III clinical trial. This research is relevant to the guideline topic and Dr. Altman has a leadership role. However, all funding goes to her institution.
Daiichi Sankyo	Direct transfer of value (meals). June 2019	1/10/2020	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for treatment of newly diagnosed, relapse and refractory AML.
BioSight	Direct transfer of value for work associated with clinical trial (see above). Flights, hotels, meals. No direct payment accepted.	1/10/2020	Indirect COI. Biosight - is developing BST-236 in phase II clinical trials for treatment of AML and the subject of the research is related to the guideline topic. However, all funding goes to Dr. Altman's institution.
Phebra	Direct transfers of value (meals)	1/10/2020	Not a COI. Phebra does not market any devices or drugs used in the diagnosis or treatment of AML.
Astellas	Direct transfers of value (meals, transportation) for participation on a steering committees and speaking.	1/10/2020	Indirect COI. Astellas markets gilteritinib for treatment of relapsed/refractory AML. Relapsed or refractory AML is out of scope for these guidelines, but gilteritinib could be indirectly affected by

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			recommendations about treatment.
Celgene	Direct transfers of value for travel and lodging, and food and beverage.		Direct COI. Celgene markets enasidenib and azacitidine for treatment of AML and is developing luspatercept for treatment of AML in phase III clinical trial.
Agios Pharmaceuticals	Direct transfer of value for food and beverage.		Direct COI. Agios is developing AG-221 for treatment of AML in phase III clinical trial.
Agios Pharmaceuticals	Research funding for clinical trial on orally administered AG-120 in subjects with Advanced Hematologic Malignancies with an IDH1 Mutation.		Indirect COI. Agios is developing AG-221 for treatment of AML in phase III clinical trial. The subject of the research is related to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
Boehringer Ingelheim	Research funding for clinical trial: Phase I monotherapy in leukemia		Indirect COI. BI 836858 was granted orphan drug status for AML by the FDA in March 2017. BI is developing volasertib for treatment of AML in Phase III clinical trial. This research is relevant to the guideline topic, however Dr. Altman does not have a leadership role and all funding goes to her institution
BMS	Research funding for clinical trial on DASFREE Ph II		Very Indirect COI. Bristol Myers Squibb is developing nivolumab

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	Dasatinib discontinuation in CP CML w stable CMR NRDG.		for treatment of AML in phase II clinical trial. However, the subject of the research is not related to the guideline topic and all funding goes to Dr. Altman's institution.
Pfizer	Research funding for A PHASE 1B2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF04449913 AN ORAL HEDGEHOG INHIBITOR IN COMBINATION WITH INTENSIVE CHEMOTHERAPY LOW DOSE ARAC OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGHRISK MYELOYDYSPLASTIC SYNDROME.		Indirect COI. Pfizer markets glasdegib for treatment of AML in older adults. (Approved in November 2018). The subject of the research is related to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
Aprea	Research funding. Drug A18-1331: A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone. Dr. Altman is the site PI	2/18/2020	Very Indirect COI. Aprea is developing APR-246 in Phase II clinical trails for treatment of AML. However, the subject of the research is not related to the guideline topic, Dr. Altman does not have a leadership role, and all funding goes to her institution.
Amphevina	Research funding. This study is a first in human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D to evaluate the safety, tolerability and preliminary	2/18/2020	Indirect COI. Amphevina is developing AMV564 in phase I clinical trials for treatment of AML and the subject of the research is related to the guideline topic. However, Dr. Altman

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	antileukemic activity of AMV564 in patients with relapsed or refractory acute myeloid leukemia (AML). Dr. Altman is the site PI.		does not have a leadership role and all funding goes to her institution.
Kura Oncology	Research funding. First-in-human (FIH) dose escalation will determine the maximum tolerated dose (MTD) of KO-539, a menin-MLL(KMT2A) inhibitor, in patients with refractory or relapsed AML who have failed or are ineligible for any approved standard of care therapies, including HSCT. Dr. Altman is the site PI.	2/18/2020	Indirect COI. Kura Oncology is developing KO 539 in Phase I clinical trails for treatment of acute leukemias. The subject of the research is related to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/23/2017; Kunkle 1/3/2018	No	Yes	Dr. Altman reports <i>previous</i> direct financial relationships with companies that market treatments for AML (Novartis, Astellas, Celgene, Immune Pharmaceuticals, Syros and Bristol Myers Squibb). She agrees to avoid such direct conflicts during the guideline development process. Dr. Altman has current research projects funded by companies that could be affected by these guidelines, including Boehringer Ingelheim, Astellas, Celgene, FUJIFILM, Bristol Myer Squibb, Pfizer, FORMA, and Millennium. Some of this research is relevant to the guideline topic, however all funding goes to her institution. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 1/5/2018	No	Yes	New disclosures. See Part D.
Alexander 6/21/2018; Kunkle 10/22/2018	No	Yes	New disclosures. See Part D.
Alexander 1/8/2019	No	Yes	New disclosures. See Part D.
Alexander 4/16/2019; Panepinto, Pai 6/19/2019	Yes	Yes	New disclosures. See Part D. Dr. Altman reports direct financial relationships with companies that market treatments for AML (AbbVie, Daiichi Sankyo). Recusal will be required.
Alexander 6/26/2019	Yes	Yes	New disclosure. See Part D.
Alexander 2/18/2020	Yes	Yes	New disclosures. See Part D. On 2/18/2020, Dr. Altman confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
AbbVie	Direct payment for participation on an advisory board	4/13/2019	Direct COI. AbbVie markets venetoclax for treatment of AML in older adults with previously untreated AML.
Daiichi Sankyo	Direct payment for participation on an advisory board.	4/13/2019	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for treatment of newly diagnosed, relapse and refractory AML.
Celgene	Direct transfers of value for travel and lodging, and food and beverage.		Direct COI. Celgene markets enasidenib and azacitidine for treatment of AML and is developing luspatercept for treatment of AML in phase III clinical trial. The subject of the research is relevant to the guideline topic. However, Dr. Altman does not have a leadership role and all funding goes to her institution.
Agios Pharmaceuticals	Direct transfer of value for food and beverage.		Direct COI. Agios is developing AG-221 for treatment of AML in phase III clinical trial.

Other Notes

Dr. Altman reports serving on a National Comprehensive Cancer Network guideline panel on AML. She is a hematologist who sees and treats patients with AML, ALL, MDS, CML and other myeloid neoplasms.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- No
- Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

- No
- Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

- No
- Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Acute Myeloid Leukemia in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Supportive

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander 6/27/2019	No	No	Dr. Brignardello-Petersen reports no financial relationships with pharmaceutical companies. As a condition of her appointment, Dr. Brignardello-Petersen agrees to avoid participating in any advisory boards, consulting, branded or non-branded talks, and to avoid any direct transfers of value from any pharmaceutical company.
Alexander 2/18/2020	No	No	On 2/18/2020, Dr. Brignardello-Petersen confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

--



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Celgene	Advisory Board participation	➤ 6 months ago (don't recall the date)	Not a COI. Celgene markets Idhifa and Vidaza for treatment of AML. However, this paid activity ended before Dr. Buckstein's appointment to the guideline panel.
Novartis	Advisory Board Participation	Sept 2016	Not a COI. Novartis markets midostaurine (Rydapt) for treatment of AML. However, this paid activity ended before Dr. Buckstein's appointment to the guideline panel.
Abbvie	Advisory Board Participation once	May 2017 (Valenica)	Not a COI. Abbvie markets venetoclax for treatment of previously untreated AML in elderly patients. However, this paid activity ended before Dr. Buckstein's appointment to the guideline panel.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Celgene	Funding for National MDS Registry run and controlled and accessed only by my institution	Director	ongoing	Indirect COI. Celgene markets Idhifa and Vidaza for treatment of AML. Dr. Buckstein has a leadership role in this project. However, the subject of the research is not related to AML, and all funding goes to her institution.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Treatment guidelines on AZA published in cancer treatment reviews. Endorsed use of vidaza for low blast (20-30%) AML based on the evidence

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
Canadian Cancer Research institute (CCSRI)	Feasibility of a randomized clinical trial assessing 2 hgb thresholds for transfusion in MDS and AML patients	PI	February 2018

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

The support is unwavering in my institution for evidence based informed clinical practice guidelines

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
- Yes

If yes, what is your primary specialty or subspecialty? All myeloid cancers and some lymphoma

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
- Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
- Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Otsuka	Funding for National MDS registry run and controlled and accessed only by Dr. Buckstein's institution. Dr. Buckstein is the registry director.	11/12/2018	Indirect COI. Otsuka markets decitabine for treatment of AML. Dr. Buckstein has a leadership role in this project. However, the subject of the research is not related to AML, and all funding goes to her institution.
Takeda	Funding for National MDS registry run and controlled and accessed only by Dr. Buckstein's institution. Dr. Buckstein is the registry director.	2/7/2020	Indirect COI. Takeda is developing pevnonedistat for treatment of AML. Dr. Buckstein has a leadership role in this project. However, the subject of the research is not related to AML, and all funding goes to her institution.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH guideline panel on acute myeloid leukemia in older adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/4/2017; Pai 12/19/2017; Kunkle 12/29/2017	No	Yes	Dr. Buckstein reports <i>previous</i> direct financial relationships with companies that market or are developing treatments for AML (Celgene, Novartis, and Abbvie). She has a current leadership role on a registry project that is funded by Celgene. The registry is not specific to the guideline topic, and funding goes to Dr. Buckstein’s institution. This indirect conflict will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 12/03/2018	No	Yes	New disclosures. See Part D.
Alexander 5/20/2019	No	Yes	On 5/7/2019, Dr. Buckstein confirmed all information in this form.
Alexander 2/14/2020	No	Yes	New disclosure. See Part D. On 2/7/2020, Dr. Buckstein confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Buckstein reports previously authoring treatment guidelines that have endorsed the use of azacytidine (Vidaza, marketed by Celgene) for low-blast (20-30%) AML. She also reports current research about AML treatment that is funded by the nonprofit Canadian Cancer Research Institute. Dr. Buckstein is a cancer specialist who treats patients with AML.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Plexxikon	Preclinical murine modeling – provision of a study drug	Local investigator or	current	Not a COI. Plexxikon markets and is developing drugs for various cancers, but none of these drugs are currently used to treat AML or are being developed for treatment of AML.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

The support from my mentors, institutions, and associated entities would be professional as might be expected of an academic community – respectful of a difference of opinions.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Hematology, Bone Marrow Transplant

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

These guidelines will address the management of older AML patients that may or may not be candidates for Bone Marrow Transplant. Therefore, decisions such as when to or when not to prescribe Bone Marrow Transplant as a clinical intervention should be addressed by these guidelines.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Actinium Pharmaceuticals	A Multicenter, Pivotal Phase 3 Study of lomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia Clinical Trial. Local PI	10/23/2018	Indirect COI. Actinium is developing lomab-B for treatment of AML and the subject of the research is related to the guideline topic. However, Dr. Choe does not have a leadership role and all funding goes to her institution.
Incyte	GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus-Host Disease. Local PI.	10/23/2018	Indirect COI. Incyte is developing drugs for treatment of AML in Phase I clinical trial. The subject of this research is indirectly related to AML. However, Dr. Choe does not have a leadership role and all funding goes to her institution.
Kamada	A PROOF OF CONCEPT PILOT TRIAL OF ALPHA-1-ANTITRYPSIN FOR PRE-EMPTION OF STEROID-REFRACTORY ACUTE GVHD Clinical Trial. Local PI.	10/23/2018	Indirect COI. Kamada is developing drugs for treatment of graft versus host disease in phase I/II clinical trials. This guideline will bone marrow transplants, and Kamada could be indirectly be affected by the recommendations of the guideline. Additionally, Dr. Choe

Company	Description	Disclosure Date	ASH Internal Notes
			does not have a leadership role and all funding goes to her institution.
Fate Therapeutics	PROTECT: A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies Clinical Trial. Local PI.	10/23/2018	Indirect COI. Fate Therapeutics is developing NK100 for treatment of AML in Phase 1 clinical trials, and ProTmune for hematologic malignancies in Phase I/II clinical trials. The subject of the research is very indirectly related to the guideline topic. Additionally, Dr. Choe does not have a leadership role and all funding goes to her institution.
Incyte	Clinical Presentation, Treatment, and Outcomes of Grade 2-4 Acute Graft Versus Host Disease (GVHD) Patients after Allogeneic Hematopoietic Stem Cell Transplants (HSCT): A Multi-Center Chart Audit Study Research Study Local PI	10/23/2018	Indirect COI. Incyte is developing drugs for treatment of AML in Phase I clinical trial. The subject of this research is indirectly related to AML. However, Dr. Choe does not have a leadership role and all funding goes to her institution.
Siemens	Dr. Choe reports that her spouse will receive royalties from the sale of a company to Siemens. The company sold to Siemens does not diagnose, treat,	2/18/2020	Not a COI. Siemen’s markets devices that could be used in the diagnosis of AML. This activity occurred after the recommendations were formed.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	manage, or alleviate health conditions.		
N/A	D.J. Hoelzle, D.M. D'Souza, A. Simeunovic, A. Asghari Adib, "Endoscopic Additive Manufacturing Tool and Method of Use," U.S. Patent Application No. 62/829,137, Provisional Application.	2/18/2020	Not a COI. This is an update to Part A, question 5. Dr. Choe's spouse does not receive any royalties from this patent.
N/A	D.J. Hoelzle, "Additive manufacturing device for biomaterials," U.S. Patent Application No: 62335438, Filed, Decision Pending.	2/18/2020	Not a COI. This is an update to Part A, question 5. Dr. Choe's spouse does not receive any royalties from this patent.
N/A	S. Zhang, J. Zartman, D.J. Hoelzle, C. Narciso. "Microfluidic devices, systems, and methods for evaluating tissue samples," 2018, U.S. Patent No: 9,975,121 B2.	2/18/2020	Not a COI. This is an update to Part A, question 5. Dr. Choe's spouse does not receive any royalties from this patent.
N/A	A.C. Rowat, D.J. Hoelzle, C.K. Chan, "Mechanical Phenotyping of Single Cells: High-Throughput Quantitative Detection and Sorting," 2016, U.S. Patent No: 9,423,234.	2/18/2020	Not a COI. This is an update to Part A, question 5. Dr. Choe's spouse does not receive any royalties from this patent.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH guideline panel on acute myeloid leukemia in older adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/4/2017; Kunkle 12/29/2017	No	No	Dr. Choe does not have any current financial conflicts of interest with for-profit companies that could be affected by these guidelines.
Alexander 11/11/2018	No	Yes	Dr. Choe reports indirect financial relationships with for-profit companies that market or are developing drugs for the treatment of AML. These indirect relationships will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 5/20/2019	No	Yes	On 5/6/2019, Dr. Choe confirmed all information in this form.
Alexander 2/19/2020	No	Yes	On 2/18/2020, Dr. Choe confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Choe is a clinical hematologist who specializes in bone marrow transplant, an intervention that is likely to be addressed by these guidelines.
--



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Agios	Ad Board	Oct 2017	Not a COI. Agios is developing AG-221 in Phase III clinical trial for treatment of AML. However, this paid activity ended before Dr. Desai’s appointment to the guideline panel.
Argenx	Ad Board	Oct 2017	Not a COI. Argenx is developing ARGX-110 in Phase II clinical trials for treatment of AML. However, this paid activity ended before Dr. Desai’s appointment to the guideline panel.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Mitsubishi Tanabe	Employee (unrelated to leukemia)	Ongoing	Indirect COI. Mitsubishi Tanabe is developing OTX-015 (a BET inhibitor) for treatment of AML in phase I clinical trial. Although OTX-015 is not to market, and the panel will not address it specifically, the panel may make recommendations about the treatment of AML that could indirectly affect OTX-015.

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Astex	Clinical trial on MPN/MDS overlap syndrome	PI	Ongoing	Indirect COI. Astex is developing SGI-110 in Phase III clinical trial for treatment of AML in adults. Dr. Desai has a leadership role in this research. However, the subject of the research is not relevant to the guideline topic and all funding goes to her institution.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I don't think there would be a concern or conflict, the panel recommendations are independent and should be of no consequence to my position or my institutions support.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Sanofi	Direct payment for participation on an advisory board. November – December 2019.	6/7/2019	Direct COI. Sanofi is developing clofarabine in phase III clinical trials for treatment of AML.
Celgene	Direct payment for participation on an advisory board. October 2018.	6/7/2019	Direct COI. Celgene markets azacitadine for treatment of AML.
Astellas	Direct payment for lecture on AML biology to the company sales force, no drugs discussed. October 2018	6/7/2019	Indirect COI. Astellas markets gilteritinib for treatment of relapsed or refractory AML. Relapsed or refractory AML is not in the scope of these guidelines, but Astellas could be indirectly affected by recommendations made by the panel, for example, if gilteritinib is approved for treatment of initial AML in the future.
Janssen Research & Development, LLC	Indirect payments to institution for study of on <i>Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory AML.</i>		Indirect COI. Janssen markets decitabine for treatment of AML.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Amgen Inc.	Indirect payment to institution for research study on <i>Adult R/R ALL Registry - Serial Chart Review</i> .		Indirect COI. Amgen is developing AMG 330 for treatment of AML in phase I clinical trials.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/12/2017; Kunkle 1/3/2018	No	Yes	Dr. Desai reports <i>previous</i> direct financial relationships with for-profit companies that could be affected by these guidelines (Agiros, Argenx). Dr. Desai has agreed to avoid direct financial conflicts for the duration of the guideline development process. Dr. Desai has a current leadership role on a research project that is funded by Astex. The research is not specific to the guideline topic and all funding goes to her institution. Her partner/spouse is employed at Mitsubishi Tanabe, which is developing a BET inhibitor for treatment of AML. Dr. Desai's indirect conflicts with Astex and Mitsubishi Tanabe will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 6/11/2019; Panepinto, Pai 6/19/2019	Yes	Yes	New disclosures. See Part D. Dr. Desai reports direct financial relationships with companies that market or are developing treatments for AML (Sanofi, Celgene, Astellas). Recusal will be required.
Alexander 2/3/2020	Yes	Yes	On 1/16/2020, Dr. Desai confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Sanofi	Direct payment for participation on an advisory board. November – December 2019.	6/7/2019	Direct COI. Sanofi is developing clofarabine in phase III clinical trials for treatment of AML.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Celgene	Direct payment for participation on an advisory board. October 2018.	6/7/2019	Direct COI. Celgene markets azacitadine for treatment of AML.

Other Notes

Dr. Desai is a medical oncologist who sees and treats patients with AML.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Agios	Consultant, Speaker	Current	Direct COI. Agios is developing AG-221 for treatment of AML in phase III clinical trial.
Amgen	Consultant	December, 2016	Not a COI. Amgen is developing AMG 330 for treatment of AML in phase I clinical trial. However, this paid activity ended before Dr. Erba’s appointment to the guideline panel.
Celgene	Consultant, Speaker	Current	Direct COI. Celgene markets enasidenib and azacytidine for treatment of AML.
Daiichi Sankyo	Consultant	Current	Direct COI. Daiichi Sankyo is developing quizartinib for treatment of AML in patients with relapsed, refractory, or newly diagnosed AML in phase III clinical trials.
Glycomimetics, Inc.	Consultant	Current	Indirect COI. Glycomimetics is developing GMI-1271 for treatment of AML in phase II clinical trial. Although GMI-1271 is not to market, and the panel will not address it specifically, the panel may make recommendations about the treatment of AML that could indirectly affect GMI-1271.
ImmunoGen	Consultant	Current	Indirect COI. ImmunoGen is developing IMG779 for treatment of AML in phase I clinical trial. Although IMG779 is not to market, and the panel will not address it specifically, the panel may make recommendations about the

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			treatment of AML that could indirectly affect IMG779.
Incyte	Consultant, Speaker	Current	Indirect COI. Incyte is developing LSD1 for treatment of AML in phase I clinical trial. Although LSD1 is not to market and the panel will not address it specifically, the panel may make recommendations about the treatment of AML that could indirectly affect LSD1.
Jazz	Consultant, Speaker	Current	Direct COI. Jazz markets Vyxeos (daunorubicin and cytarabine) for treatment of AML in adults with newly diagnosed t-AML or AML-MRC.
MacroGenics	Consultant	June, 2017	Not a COI. MacroGenics developing flotetuzumab for treatment of AML in Phase I clinical trials. However, this paid activity ended before Dr. Erba's appointment to the guideline panel.
Novartis	Consultant, Speaker	Current	Direct COI. Novartis markets midostaurin (Rydapt) for treatment of AML.
Ono	Consultant	December, 2016	Not a COI. Ono is developing ONO-7475 for treatment of AML in phase I clinical trial. However, this paid activity ended before Dr. Erba's appointment to the guideline panel.
Pfizer	Consultant	December, 2016	Not a COI. Pfizer is developing glasdegib for treatment of AML in phase II clinical trial. However, this paid activity ended before Dr. Erba's appointment to the guideline panel.
Seattle Genetics	Consultant	Current	Direct COI. Seattle Genetics is developing vadastuximab talirine for treatment of AML.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Sunesis	Consultant	December, 2015	Not a COI. Sunesis is developing vosaroxin for treatment of AML in phase II clinical trials. However, this paid activity ended before Dr. Erba's appointment to the guideline panel.
Takeda/Millennium	Consultant	Current	Direct COI. Takeda Oncology is developing TAK-659 in Phase III clinical trial for treatment of AML.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Agios	Clinical trial, IDH1m inhibitor in AML	PI	Current	Indirect COI. Agios is developing AG-221 for treatment of AML in Phase III clinical trial. Dr. Erba has a leadership role and the subject of this research is relevant to the guideline topic. However, all funding goes to his institution.
Amgen	Clinical trial, MDM2 inhibitor, CD33 BiTE in AML	PI	Current	Indirect COI. Amgen is developing AMG 330 for treatment of AML in phase I clinical trial. Dr. Erba has a leadership role and the subject of the research is relevant to the guideline

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				topic. However, all funding goes to his institution.
Astellas	Clinical trial, FLT3 inhibitor in AML	PI	Current	Indirect COI. Astellas is developing gilterinib for treatment of AML in phase III clinical trial. Dr. Erba has a leadership role and the research is relevant to the guideline topic. However, all funding goes to his institution.
Celator	Clinical trial, CPX351 in AML	PI	Closed	Not a COI. Celator was acquired by Jazz Pharmaceuticals, which markets Vyxeos for treatment of AML. However, this clinical trial ended before Dr. Erba's appointment to the guideline panel.
Celgene	AML Registry	Chair, steering committee		Indirect COI. Celgene markets enasidenib and azacitidine for treatment of AML. Dr. Erba has a leadership role and the subject of the research is relevant to the guideline topic. However, all funding goes to his institution.
Daiichi Sankyo	Clinical trial, QUANTUM First Phase III trial	Chair, steering committee	Current	Indirect COI. Daiichi Sankyo is developing quizartinib for treatment of AML in phase III clinical trial. Dr. Erba has a leadership role and the subject of the research is relevant to the guideline topic. However, all funding goes to his institution.
Glycomimetics	Clinical trial, Phase I	Chair, DSMB	09/2017	Not a COI. Glycomimetics is developing GMI-1271 for treatment of AML in phase II clinical trial. However, this clinical trial ended before Dr.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				Erba's appointment to the guideline panel.
ImmunoGen	Clinical trial, anti CD33 and anti CD12 ADC	PI	Current	Indirect COI. ImmunoGen is developing IMG779 for treatment of AML in phase I clinical trial. Dr. Erba has a leadership role and the subject of the research is relevant to the guideline topic. However, all funding goes to his institution.
Janssen	Clinical trial, telomerase inhibitor in MDS and MF	PI	Current	Indirect COI. Janssen markets decitabine for treatment of AML in Europe, and decitabine is in phase III clinical trial for treatment of AML in the US. Dr. Erba has a leadership role. However, the subject of the research is not relevant to the guideline topic and all funding goes to his institution.
Seattle Genetics	Clinical trial, anti CD33 and anti CD123 ADC in AML	PI	Current	Indirect COI. Seattle Genetics is developing vadastuximab talirine for treatment of AML in phase III clinical trials. Dr. Erba has a leadership role and the subject of the research is relevant to the guideline topic. However, all funding goes to his institution.
Takeda	Clinical trial, NAE inhibitor and FLT3 inhibitor in AML	PI	Current	Indirect COI. Takeda is developing TAK-659 for treatment of AML in phase III clinical trial. Dr. Erba has a leadership role and the subject of the research is relevant to the guideline topic. However, all funding goes to his institution.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guidelines on Acute Myeloid Leukemia in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: I care for older patients with acute myeloid leukemia. My positions and opinions are based on the literature and my own personal experience with my patients.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Michaelis LC, **Erba HP**. Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014. *Curr Opin Hematol*. 2015 Mar;22(2):108-15.

Erba HP. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. *Leuk Res*. 2015 Feb; 39(2):183-9.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
National Cancer Institute	SWOG	Chair, Leukemia Committee	Current
National Cancer Institute	Leukemia Steering Committee	Member	Current
National Cancer Institute	UAB Lead Academic Performing Site (LAPS)	PI of LAPS Grant at UAB	Current
National Cancer Institute	SWOG grant at UAB	PI	Current

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain: I see patients with acute myeloid leukemia at the UAB Kirklin Clinic and Hospitals. The institution receives the clinical revenues for this activity.

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Neutral

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty? Hematology/Medical Oncology. My practice is restricted to patients with acute leukemia, myelodysplastic syndromes and myeloproliferative neoplasms.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain: I treat older patients with acute myeloid leukemia with commercially available agents (on and off label) and investigational agents on clinical trials.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe: I am frequently asked to speak on this topic (therapy of older patients with AML)

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Pfizer	Direct payment consulting related to glasdegib and gemtuzumab ozogamicin	5/17/2019	Direct COI. Pfizer markets glasdegib for treatment of AML in older adults who are not candidates for intensive chemotherapy and gemtuzumab ozogamicin for treatment of AML.
Astellas	Direct payment for consulting related to gilteritinib	5/17/2019	Indirect COI. Astellas markets gilteritinib for treatment of relapsed or refractory AML. Relapsed or refractory AML is out of scope for these guidelines, but Astellas could be indirectly affected by recommendations the panel makes about the treatment of AML.
Celgene	Direct payment for speaking and consulting related to enasidenib	5/17/2019	Direct COI. Celgene markets azacitidine for the treatment of AML.
Daiichi Sankyo	Direct payment for consulting related to quizartinib	5/17/2019	Direct COI. Daiichi Sankyo is developing quizartinib for treatment of newly diagnosed AML in phase III clinical trials
Glycomimetics	Direct payment for consulting related to uproleselan	5/17/2019	Indirect COI. Glycomimetics is developing uproleselan in Phase III clinical trials for treatment of

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			relapsed or refractory AML. Relapsed or refractory AML is out of scope for this guideline and the product is not yet to market, however Glycomimetrics could be indirectly affected by recommendations the panel makes about treatment of AML.
National Cancer Institute	Dr. Erba is no longer the PI of LAPS grant at UAB.	5/17/2019	This is an update to Part C, Question 3.
N/A	Dr. Erba's institutional affiliation changed from UAB to Duke University, Division of Hematologic Malignancies and Cellular Therapy in the Division of Medicine and in the Duke Cancer Institute	5/17/2019	This is an update to institutional affiliation.
Covance	Direct payment for participation on independent review committee for AbbVie phase III studies of venetoclax in older, unfit AML patients.	1/14/2020	Indirect COI. Covance is a contract research organization and does not market any drugs or devices related to the diagnosis or treatment of AML. However, AbbVie is developing venetoclax, in phase III clinical trials, for treatment of AML in older adults.
AbbVie	Direct payment for consulting	1/14/2020	Direct COI. AbbVie is developing venetoclax, in phase III clinical trials, for treatment of AML in older adults.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Pfizer	Research funding for AN OPENLABEL PHASE 1B STUDY OF PF04449913 GLASDEGIB IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHERRISK MYELOYDYSPLASTIC SYNDROME ACUTE MYELOID LEUKEMIA OR CHRONIC MYELOMONOCYTIC LEUKEMIA. (2018)	2/21/2020	Indirect COI. Pfizer markets glasdegib for treatment of AML in older adults who are not candidates for intensive chemotherapy and gemtuzumab ozogamicin for treatment of AML.
Amgen	Direct transfers of value for travel and lodging and food and beverage. (2018)	2/21/2020	Indirect COI. Amgen is developing AMG 330 for treatment of AML in phase I clinical trial.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/21/2017; Pai 12/24/2017; Kunkle 1/3/2018	Yes	Yes	<p>Dr. Erba has direct financial relationships with companies that market therapies for AML and therefore could be affected by these guidelines, including Agios, Celgene, Daiichi Sankyo, Jazz, Novartis, Seattle Genetics and Takeda (see summary below). Recusal will be required for these conflicts if they are specific to any recommendation. Dr. Erba reports that he expects to continue to do paid activities including speaking for such companies during the guideline development process.</p> <p>Dr. Erba also has a leadership role on research projects specific to AML treatment that are funded by Agios, Astellas, Celgene, Daiichi Sankyo, Janssen, Seattle Genetics and Takeda. All funding goes to his institution. These indirect conflicts will be managed through disclosure and panel composition.</p>
Alexander 11/12/2018	Yes	Yes	On 11/11/2018, Dr. Erba confirmed all information in this form.
Alexander 5/20/2019	Yes	Yes	New disclosures. See Part D. Dr. Erba reports new direct financial relationships with companies that market or are developing treatments for AML (Pfizer, Astellas, Daiichi Sankyo, Glycomimetics, Takeda). These relationships will trigger recusal for relevant recommendations.
Alexander 2/18/2020	Yes	Yes	New disclosures. See Part D. On 1/14/2020, Dr. Erba confirmed all information in this form.
Alexander 2/21/2020	Yes	Yes	New disclosures. See Part D. On 2/21/2020, Dr. Erba confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Agios	Personal income from consulting and speaking	12/18/2017	Direct COI. Agios is developing AG-221 for treatment of AML in phase III clinical trial.
Celgene	Personal income from consulting and speaking	12/18/2017	Direct COI. Celgene markets enasidenib and azacytidine for treatment of AML.
Daiichi Sankyo	Personal income from consulting	12/18/2017	Direct COI. Daiichi Sankyo is developing quizartinib for treatment of newly diagnosed AML in phase III clinical trials.
Jazz	Personal income from consulting and speaking	12/18/2017	Direct COI. Jazz markets Vyxeos (daunorubicin and cytarabine) for treatment of AML in adults with newly diagnosed t-AML or AML-MRC.
Novartis	Personal income from consulting and speaking	12/18/2017	Direct COI. Novartis markets midostaurin (Rydapt) for treatment of AML.
Seattle Genetics	Personal income from consulting	12/18/2017	Direct COI. Seattle Genetics is developing vadastuximab talirine for treatment of AML.
Takeda/Millennium	Personal income from consulting	12/18/2017	Direct COI. Takeda Oncology is developing TAK-659 in Phase III clinical trial for treatment of AML.
Pfizer	Direct payment consulting related to glasdegib and gemtuzumab ozogamicin	5/17/2019	Direct COI. Pfizer markets glasdegib for treatment of AML in older adults who are not candidates for

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
			intensive chemotherapy and gemtuzumab ozogamicin for treatment of AML.
Celgene	Direct payment for speaking and consulting related to enasidenib	5/17/2019	Direct COI. Celgene markets azacitidine for the treatment of AML.
Daiichi Sankyo	Direct payment for consulting related to quizartinib	5/17/2019	Direct COI. Daiichi Sankyo is developing quizartinib for treatment of newly diagnosed AML in phase III clinical trials
AbbVie	Direct payment for consulting	1/14/2020	Direct COI. AbbVie is developing venetoclax, in phase III clinical trials, for treatment of AML in older adults.

Other Notes

Dr. Erba reports being the chair of the Leukemia Steering Committee for SWOG. He has authored opinions about optimal treatment of older patients with AML. He receives research funding from the National Cancer Institute. As a hematologist and oncologist, he sees and treats older patients with AML.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Acute Myeloid Leukemia in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

No particular support

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

General internal medicine

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander 1/17/2018	No	No	Dr. Guyatt has no current financial relationships with for-profit companies that could be affected by these guidelines. As a condition of his appointment, he has agreed to avoid all direct financial conflicts of interest during the guideline development process.
Alexander 6/28/2018	No	No	On 6/13/2018, Dr. Guyatt confirmed all information in this form.
Alexander 2/18/2020	No	No	On 2/18/2020, Dr. Guyatt confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

--



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Merck	Subject: Clinical Trial - NCT02996474 (Pembrolizumab and decitabine for refractory or relapsed AML) (NIH approved CRADA – funding).	PI	Ongoing	Indirect COI. Merck, in partnership with Mitsubishi Tenabe, is developing OTX-015 (a BET inhibitor) for treatment of AML in Phase I clinical trial. The subject of the research is related to the guideline topic and Dr. Hourigan has a leadership role. However, all funding goes to his institution.
Sellas	Subject: AML MRD for use in Clinical Trials	PI	Ongoing	Indirect COI. Sellas is developing galinpepimut-s in Phase II clinical trial for treatment of AML. The subject of the research is

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	(NIH approved CRADA- funding)			related to the guideline topic and Dr. Hourigan has a leadership role. However, all funding goes to his institution.
Qiagen	Research Collaboration (Unofficial) – Subject: AML MRD – low or no cost reagents	PI	Ongoing	Very Indirect COI. Qiagen markets assays used in the diagnosis of AML and Dr. Hourigan has a leadership role. The subject of the research is indirectly related to the guideline topic and all funding goes to his institution.
Archer	Research Collaboration (Unofficial) – Subject: AML MRD – low cost reagents	PI	Ongoing	Very Indirect COI. Archer markets assays used in the diagnosis of AML and Dr. Hourigan has a leadership role. However, the subject of the research is indirectly related to the guideline topic and all funding goes to his institution.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Johns Hopkins School of Medicine	Part-Time Associate Professor of Oncology (Clinical Work)	Paid	Ongoing	Not a COI. Johns Hopkins School of Medicine does not market any drugs or devices used in the diagnosis or treatment of AML.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Acute Myeloid Leukemia in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

1) **I run the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute, and have published extensively in area of AML:** https://www.ncbi.nlm.nih.gov/pubmed/?term=hourigan_cs

2) **I am a member of the European Leukemia Network (ELN) International Consensus Committee on measurable residual disease (MRD) in acute myeloid leukemia.**

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
NHLBI, NIH	I run a laboratory and clinical research program in the intramural program of the NIH focusing on AML, specifically measurable residual disease (MRD) in AML.	PI	Ongoing

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Strong support.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
- Yes

If yes, what is your primary specialty or subspecialty?

Board-certified in Internal Medicine, Hematology and Medical Oncology. My specialist interest is adult patients with AML, although I also see patients with other hematological malignancies.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
- Yes

If yes, please explain: Yes, as above.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
- Yes

If yes, please describe: **As part of my NIH official duties, I attend industry advisory boards (no-compensation or any reimbursement from industry) on the topic of AML MRD. In addition to NIH supervisory approval, these activities are always prospectively cleared by the NHLBI ethics office.**

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander 6/27/2019; Hicks 6/27/2019	No	Yes	<p>Dr. Hourigan reports research funding from companies that market or are developing drugs or devices used in the treatment and diagnosis of AML (Merck, Sellas, Qiagen, Archer). These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.</p> <p>Dr. Hourigan reports that as an NIH employee he attends advisory boards on the topic of minimal residual disease in AML. He confirmed that he does not receive any transfers of value from pharmaceutical companies for these activities (payment, transportation, lodging or meals), and that the activity must be cleared by the NHLBI ethics office. Dr. Hourigan agreed to avoid all future ad boards, unless required by his job.</p> <p>As a condition of his appointment Dr. Hourigan agrees to avoid any consulting, speaker's bureaus, branded or non-branded talks, and to avoid any direct transfers of value from any pharmaceutical company.</p>
Alexander 2/4/2020	No	Yes	On 1/20/2020, Dr. Hourigan confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

--



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Celgene	Honoraria for non-branded educational talks on myelodysplastic syndromes	Current	Direct COI. Celgene markets Vidaza and Idhifa for treatment of AML.
Helsinn Therapeutics	One-time advisory board meeting about cancer cachexia	08/2016	Not a COI. Helsinn markets drugs for the treatment of chemotherapy related nausea and vomiting, so the company could be indirectly affected if these guidelines offer recommendations about chemotherapy. However, this paid activity ended before Dr. LeBlanc’s appointment to the guideline panel.
Quintiles	Events adjudication for clinical trials (not oncology trials)	Current	Not a COI. IMS Health and Quintiles merged to form IQVIA. IQVIA does not market any drugs or devices used in the diagnosis or treatment of AML.
Epi-Q/Janssen	Consulting	08/2016	Not a COI. Epi-Q is a consulting firm and does not market any drugs or devices used in the diagnosis or treatment of AML. Janssen markets decitabine in the EU for treatment of AML in adults. Decitabine is in Phase III clinical trial in the US. However, this paid activity ended before Dr. LeBlanc’s appointment to the guideline panel.
Flatiron Health	Consulting	12/2016	Not a COI. Flatiron does not market any products or devices used in the diagnosis or treatment of AML.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Pfizer	One-time advisory board	05/2016	Not a COI. Pfizer is developing Imbruvica in Phase II clinical trial, glasdegib in Phase II clinical trial and clofarabine in phase III clinical trial for the treatment of AML. However, this paid activity ended before Dr. LeBlanc's appointment to the panel.
Helsinn Therapeutics	Consulting	06/2017	Not a COI. Helsinn markets drugs for the treatment of chemotherapy related nausea and vomiting, so the company could be indirectly affected if these guidelines offer recommendations about chemotherapy. However, this paid activity ended before Dr. LeBlanc's appointment to the panel.
Otsuka US	One-time advisory board, and ongoing consulting regarding outcomes research	Current	Direct COI. In partnership with Janssen, Otsuka markets decitabine for treatment of adults >65 years with acute myeloid leukemia in the EU. Decitabine is in phase III clinical trial in the US.
Heron	Advisory Board about chemo-induced nausea/vomiting	10/2017	Not a COI. Heron markets granisetron and aprepitant for prevention of nausea and vomiting associated with chemotherapy, so the company could be indirectly affected if these guidelines offer recommendations about chemotherapy. However, this paid activity ended before Dr. LeBlanc's appointment to the panel.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Seattle Genetics	A retrospective data analysis of Hodgkin lymphoma patients	PI	Current	Indirect COI. Seattle Genetics is developing vadastuximab talirine and SGN-CD123A for treatment of AML in Phase III clinical trials. Dr. LeBlanc has a leadership role in this research, however the research is not related to AML and all funding goes to his institution.
AstraZeneca	Collaborative development of a supportive care application for patients with cancer	On-site Project leader	Current	Indirect COI. AstraZeneca part of Otsuka group. Otsuka, in partnership with Janssen, markets decitabine for treatment of patients >65 with AML in the EU.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				Decitibine is in phase III clinical trial in the US. This project is related (although not specifically) to AML, and Dr. LeBlanc has a leadership role. However, all funding goes to his institution.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in older adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I do patient experience research in AML patients, describing their experiences of illness, and working to improve upon the standard of care regarding symptoms, quality of life, and distress. In doing so, I have written and talked about these issues, in medical literature, poster presentations, and interviews. None of this content really relates to favoring a particular therapy, however.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain: I am answering yes because my clinical practice focuses mostly on myeloid malignancies, so I have many AML patients in my clinic, which does generate revenue for my institution. Since this guideline is about AML management, my experience makes me a good candidate to meaningfully contribute; I wouldn't imagine this to be a conflict, but the wording of this question makes it seem like I should disclose that I indeed see and treat these kinds of patients.

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My institution tends not to get involved in issues like this, as they relate to nuances of clinical practice that only specialists are expert in. That said, if there were a major problem or fallout from the guideline recommendations I expect that my institution would be supportive of me and my involvement, as they have always supported me and my work.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
- Yes

If yes, what is your primary specialty or subspecialty? I am a medical oncologist and palliative care physician, in terms of board certifications. My clinical focus in this role is in myeloid malignancies, so I patients with AML, MDS, CML, and related diseases.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
- Yes

If yes, please explain: I provide treatments for patients with AML, the topic of the guideline.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
- Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Agios	Direct payment for participation on an advisory board	4/23/2019	Direct COI. Agios markets ivosidenib for treatment of AML in newly diagnosed patients over 75 who are not candidates for intensive chemotherapy.
Amgen	Direct payment for participation on an advisory board (related to myeloma)	4/23/2019	Indirect COI. Amgen is developing AMG 330, AMG 427, and AMG 673 in Phase I clinical trials for treatment of AML.
AbbVie	Direct payment for participation on an advisory board and non-branded speaking engagements about AML.	4/23/2019	Direct COI. AbbVie markets venetoclax for treatment of AML in adults over 75 who are not candidates for intensive chemotherapy.
Daiichi Sankyo	Direct payment for participation on an advisory board	4/23/2019	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for the treatment of newly diagnosed AML. Quizartinib is also marketed for treatment of relapsed or refractory AML. However, relapsed or refractory AML is out of scope for these guidelines.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Amgen	Direct payment for consulting on myeloma	4/23/2019	Indirect COI. Amgen is developing AMG 330 in Phase I clinical trials for treatment of AML.
Pfizer	Direct payment for consulting on health equity and outcomes research project related to AML	4/23/2019	Direct COI. Pfizer markets glasdegib for treatment of AML in combination with non-intensive chemotherapy.
AstraZeneca	Direct payment for consulting on health equity and outcomes research project related to CLL	4/23/2019	Indirect COI. AstraZeneca is developing drugs in Phase I clinical trials for the treatment of AML.
Daiichi Sankyo	Direct payment for consulting on health equity and outcomes research project related to AML	4/23/2019	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for the treatment of newly diagnosed AML. Quizartinib is also marketed for treatment of relapsed or refractory AML. However, relapsed or refractory AML is out of scope for these guidelines.
Seattle Genetics	Direct payment for consulting on health equity and outcomes research project related to Hodgkin lymphoma and PTCL	4/23/2019	Direct COI. Seattle Genetics is developing vadastuximab talirine in phase III clinical trials for treatment of AML in older adults.
Covance	Member of the events adjudication committee for an AbbVie trial of venetoclax in AML; it's an independent review committee through Covance. AbbVie funds	4/23/2019	Indirect COI. Covance is a contract research organization that provides clinical trials oversight, drug development consulting, and other services to

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	the work through Covance.		pharmaceutical companies.
Celgene	Direct payment for speaking. Non-branded webinar for the College of American Pathologists on AML diagnosis, risk stratification, and testing	4/23/2019	Direct COI. Celgene markets azacitadine for treatment of AML.
Agios	Direct payment for speaking. Non-branded talk about AML treatment paradigms	4/23/2019	Direct COI. Agios markets ivosidenib for treatment of AML in newly diagnosed patients over 75 that are not candidates for intensive therapy.
Jazz Pharmaceuticals	Research funding for study on health economics and outcomes research project in AML	4/23/2019	Direct COI. Jazz markets daunorubicin and cytarabine for treatment of AML.
Agios	Direct payment for speaking on ivosidenib in IDH1 mutated AML	4/23/2019	Direct COI. Agios markets ivosidenib for treatment of AML in newly diagnosed patients over 75 that are not candidates for intensive therapy.
Celgene	Direct payment for speaking on enasidenib in IDH2 mutated AML	4/23/2019	Direct COI. Celgene markets azacitadine for treatment of AML.
Otsuka	This activity ended in 2018 and will not resume.	4/23/2019	This is an update to Part A, Question 4.
Quintiles/IQVia	This activity ended.	4/23/2019	This is an update to Part A, Question 4.
Helsinn	This activity ended.	4/23/2019	This is an update to Part A, Question 4.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Jazz Pharmaceuticals	Direct payments for food and beverages (2018)	2/21/2020	Direct COI. Jazz markets daunorubicin and cytarabine for treatment of AML.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/6/2017; Pai, 12/19/2017; Kunkle 1/3/2018	Yes	Yes	Dr. LeBlanc has direct financial conflicts with Celgene and Otsuka (see summary below). Recusal will be required for these conflicts if they are specific to any recommendation. Dr. LeBlanc has a leadership role on research projects funded by Seattle Genetics and by AstraZeneca, both companies that market treatments for AML. Neither research project is specific to AML, and funding goes to Dr. LeBlanc's institution. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 5/15/2019	Yes	Yes	New interests disclosed. See Part D. Dr. LeBlanc disclosed new direct financial conflicts with companies that market or are developing treatments for AML (Agiost, AbbVie, Daiichi Sankyo, Pfizer, Seattle Genetics, Jazz). Recusal will be required.
Alexander 2/3/2020	Yes	Yes	On 1/13/2020, Dr. LeBlanc confirmed all information in this form.
Alexander 2/21/2020	Yes	Yes	New interest disclosed. See Part D. On 2/21/2020, Dr. LeBlanc confirmed this disclosure.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Celgene	Personal income for non-branded educational talks on	11/18/2017	Direct COI. Celgene markets azacitidine for treatment of AML.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
	myelodysplastic syndromes		
Otsuka US	Personal income for one-time advisory board and for ongoing consulting regarding outcomes research	11/18/2017	Direct COI. In partnership with Janssen, Otsuka markets decitabine for treatment of adults >65 years with acute myeloid leukemia in the EU.
Agios	Direct payment for participation on an advisory board	4/23/2019	Direct COI. Agios markets ivosidenib for treatment of AML in newly diagnosed patients over 75 who are not candidates for intensive chemotherapy.
AbbVie	Direct payment for participation on an advisory board	4/23/2019	Direct COI. AbbVie markets venetoclax for treatment of AML in adults over 75 who are not candidates for intensive chemotherapy.
Daiichi Sankyo	Direct payment for participation on an advisory board	4/23/2019	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for the treatment of newly diagnosed AML. Quizartinib is also marketed for treatment of relapsed or refractory AML. However, relapsed or refractory AML is out of scope for these guidelines.
Pfizer	Direct payment for consulting on health equity and outcomes	4/23/2019	Direct COI. Pfizer markets glasdegib for treatment of AML in combination with non-

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
	research project related to AML		intensive chemotherapy.
Daiichi Sankyo	Direct payment for consulting on health equity and outcomes research project related to AML	4/23/2019	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for the treatment of newly diagnosed AML. Quizartinib is also marketed for treatment of relapsed or refractory AML. However, relapsed or refractory AML is out of scope for these guidelines.
Seattle Genetics	Direct payment for consulting on health equity and outcomes research project related to Hodgkin lymphoma and PTCL	4/23/2019	Direct COI. Seattle Genetics is developing vadastuximab talirine in phase III clinical trials for treatment of AML in older adults.
Celgene	Direct payment for speaking. Non-branded webinar for the College of American Pathologists on AML diagnosis, risk stratification, and testing	4/23/2019	Direct COI. Celgene markets azacitadine for treatment of AML.
Agios	Direct payment for speaking. Non-branded talk about AML treatment paradigms	4/23/2019	Direct COI. Agios markets ivosidenib for treatment of AML in newly diagnosed patients over 75 that are not candidates for intensive therapy.
Jazz Pharmaceuticals	Research funding for study on health economics and outcomes research project in AML	4/23/2019	Direct COI. Jazz markets daunorubicin and cytarabine for treatment of AML.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Agios	Direct payment for speaking on ivosidenib in IDH1 mutated AML	4/23/2019	Direct COI. Agios markets ivosidenib for treatment of AML in newly diagnosed patients over 75 that are not candidates for intensive therapy.
Celgene	Direct payment for speaking on enasidenib in IDH2 mutated AML	4/23/2019	Direct COI. Celgene markets azacitadine for treatment of AML.
Jazz Pharmaceuticals	Direct payments for food and beverages (2018).	2/12/2020	Direct COI. Jazz markets daunorubicin and cytarabine for treatment of AML.

Other Notes

Dr. LeBlanc reports that he has written and talked about therapies for AML and about the disease experiences of patients with AML. As a medical oncologist and palliative care physician, he sees and treats patients with AML, MDS, CML and related diseases.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Astellas	Phase I/II open-label, dose escalation study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of ASP2215 in pts with relapsed or refractory AML (2215-CL-0101)	Local PI	On-going	Indirect COI. Astellas is developing gilteritinib in phase III clinical trials for treatment of AML and the subject of the research is relevant to the guideline topic. However, Dr. Litzow does not have a leadership role and all funding goes to his institution.
Amgen	E1910, A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults	National PI	On-going	Very Indirect COI. Amgen is developing AMG 330 for treatment of AML in Phase I clinical trials. However, Dr. Litzow does not have a leadership role (this is an international trial), the subject of the research is not relevant

Company	Description of Research	My Role	End Date	For ASH Internal Use
				to the guideline topic and all funding goes to his institution.
Actinium	Iomab-01, A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia (IOMAB)	Local PI	On-going	Indirect COI. Actinium is developing Iomab-B CD45 in phase III clinical trial as an induction and conditioning agent prior to a bone marrow transplant for patients over 55 with relapsed or refractory AML. The subject of the research is relevant to the guideline topic. However, Dr. Litzow does not have a leadership role and all funding goes to his institution.
Novartis	CPKC412AUS56X, An open-label, multi-center, expanded treatment protocol of midostaurin in adult pts with newly diagnosed FLT3-mutated Acute Myeloid Leukemia	Local PI	On-going	Indirect COI. Novartis markets midostaurin (Rydapt) for treatment of AML and the subject of the research is relevant to the guideline topic. However, Dr. Litzow does not have a leadership role and all funding goes to his institution.
Miltenyi	BMT CTN 1301, A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease.	Local PI	On-going	Indirect COI. Miltenyi markets flow cytometers, which are used in the diagnosis of AML. However, it is unlikely that questions about diagnosis will be within the scope of the guideline. The subject of the research is relevant to the guideline topic, however Dr. Litzow does not have a leadership role and all funding goes to his institution.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would be strongly supported.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
- Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
- Yes

If yes, please explain: I treat elderly patients with AML and perform and recommend diagnostic tests, evaluations, treatments, and procedures.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
- Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Astellas	Research Funding. Local PI of BMT CTN 1506, A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.	10/19/2018	Indirect COI. Astellas markets gilteritinib for treatment of relapsed or refractory AML. However, all funding goes to Dr. Litzow's institution, he does not have a leadership role, and relapsed/refractory AML is out of scope for these guidelines.
Tolero	Research funding. Local PI for TPI-ALV-201, A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML and Exploratory Arms with Varying Levels of MCL-1 Dependence. Local PI	10/19/2018	Indirect COI. Tolero is developing alvocidib for treatment of AML in Phase II clinical trials. However, all funding goes to Dr. Litzow's institution and he does not have a leadership role.
Sanofi	Direct payment for participation in advisory board. December 2018.	4/16/2019	Direct COI. Sanofi is developing clofarabine for treatment of AML.
Pluristem	A Phase 1 Open-Label Dose-Escalation Study	4/16/2019	Very Indirect COI. Pluristem markets and is developing products used in bone marrow

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	to Evaluate the Safety of Intra-Muscular Injections of PLX-R18 in Subjects with Incomplete Hematopoietic Recovery following Hematopoietic Cell Transplantation. Local PI		transplant. However, the guideline panel will not be making specific recommendations about transplantation. Additionally, the research is unrelated to the guideline topic, all funding goes to Dr. Litzow's institution, and he does not have a leadership role.
AbbVie	A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia Local PI.	4/16/2019	Indirect COI. AbbVie markets venetoclax for treatment of AML in older adults and the research is related to the guideline topic. However, all funding goes to Dr. Litzow's institution and he does not have a leadership role.
NewLink Genetics	Direct payment for participation on an advisory board. June 2019.	1/10/2020	Indirect COI. NewLink Genetics is developing indoximod for treatment of newly diagnosed AML in phase I clinical trials.
Servier Pharmaceuticals LLC	Research funding as PI in a phase III randomized trial of Blinatumomab for newly diagnosed bcr-abl-negative lineage acute lymphoblastic leukemia in adults.		Very Indirect COI. Servier Pharmaceuticals is developing an Mcl1 inhibitor in phase I clinical trials for potential treatment of AML. Dr. Litzow is the PI. However, the research is not related to the guideline topic, and all funding goes to Dr. Litzow's institution.
Boehringer Ingelheim	Research funding for study (BAML-16-001-		Indirect COI. Boehringer Ingelheim

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	S2/BI 836858 with 5-Aza).		is developing volasertib in phase III clinical trials for treatment of AML and the subject of the research is related to the guideline topic. However, Dr. Litzow does not have a leadership role and all funding goes to Dr. Litzow's institution.
Omeros	Direct payment for participation on an advisory board.	2/23/2020	Indirect COI. Omeros is developing OMS721 for treatment of HSCT associated TMA in Phase III clinical trials.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/12/2017; Pai 12/24/2017; Kunkle 1/3/2018	No	Yes	Dr. Litzow is involved in research projects funded by companies that market or are developing drugs used for the treatment of AML, including Astellas, Actinium, Novartis and Miltenyi. However, Dr. Litzow does not have a leadership role in any of these projects, and all funding goes to his institution. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 10/24/2018	No	Yes	New disclosures. See Part D.
Alexander 4/21/2019; Panepinto, Pai 6/19/2019	Yes	Yes	New disclosures. See Part D. Dr. Litzow reports new research projects, and a direct financial relationship a company that markets a drug used in the treatment of AML (Sanofi). Recusal will be required.
Alexander 2/14/2020	Yes	Yes	New disclosure. See Part D. On 1/10/2020 Dr. Litzow confirmed all information in this form.
Alexander 2/23/2020	Yes	Yes	New disclosures. See Part D. On 2/23/2020, Dr. Litzow confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Sanofi	Direct payment for participation in advisory board. December 2018.	4/16/2019	Direct COI. Sanofi is developing clofarabine for treatment of AML.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Litzow is a hematologist who specializes in hematologic oncology. He sees and treats older patients with AML, and performs and recommends diagnostic tests, evaluations, treatments, and procedures.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>
Novartis	Stock \$23 000	12/13/2017	Not a COI. Divested before Dr. MacEachern's appointment to the guideline panel.
Johnston and Johnston	Stock \$21 000	12/13/2017	Not a COI. Divested before Dr. MacEachern's appointment to the guideline panel.

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Amgen	ITP Advisory board	Nov 2017	Not a COI. Amgen is developing AMG 330 in phase I clinical trials for treatment of AML. However, this paid activity ended before Dr. MacEachern’s appointment to the guideline panel.
Amgen	Carlizomib myeloma Advisory board	Oct 2017	Not a COI. Amgen is developing AMG 330 in phase I clinical trials for treatment of AML. However, this paid activity ended before Dr. MacEachern’s appointment to the guideline panel.
Roche	CLL Advisory board	November 2017	Not a COI. Roche markets ventoclax for treatment of AML in older adults. However, this financial relationship ended before Dr. MacEachern’s appointment to the guideline panel.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution? No concerns

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty? Malignant hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I work at a full service acute leukemia center (but we do not do transplants)

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Janssen	Moderator for an educational event at Grand River Regional Cancer Centre: "IGHV mutational status and CLL." October 2018	10/29/2018	Not a COI. This activity was supported by Janssen. Although Janssen markets decitabine for treatment of AML, the activity met ACCME criteria intended to prevent commercial influence over content.
Novartis	Moderator for an educational event at Grand River Regional Cancer Centre: "CML: changing goals of treatment" focused on the future of discontinuation of long term TKI therapy.	10/29/2018	Not a COI. This activity was supported by Novartis. Although Novartis markets midostaurin for treatment of AML, the activity met ACCME criteria intended to prevent commercial influence over content.
Janssen	Direct payment for participation in an advisory board on ibrutinib in CLL and MCL. March 2019.	4/10/2019	Direct COI. Janssen markets decitabine for treatment of AML.
Amgen Canada	Direct payment for participation in an advisory board on multiple myeloma and carfilzomib. February 2019.	4/10/2019	Indirect COI. Amgen is developing AMG 330 for treatment of AML in phase I clinical trials.
Novartis	Direct payment for participation in an advisory board on polycythemia rubra	4/10/2019	Direct COI. Novartis markets midostaurin for treatment of AML.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	vera and ruxolitinib. March 2019.		

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/14/2017; Kunkle 1/3/2018	No	No	Dr. MacEachern reports <i>previous</i> direct financial relationships with companies that market or are developing drugs that treat AML (Roche, Amgen). By email, on 12/13/17, Dr. MacEachern confirmed that she will avoid direct financial conflicts of interest such as these for the duration of the guideline development process.
Alexander 11/11/2018	No	No	New disclosures. See Part D.
Alexander 4/15/2019	Yes	Yes	Dr. MacEachern reports direct financial relationships with companies that markets or are developing drugs that treat AML (Janssen, Amgen, Novartis). These conflicts will be managed through recusal.
Alexander 5/20/2019; Panepinto, Pai 6/19/2019	Yes	Yes	On 05/06/2019, Dr. MacEachern confirmed all information in this form.
Alexander 2/3/2020	Yes	Yes	On 1/21/2020, Dr. MacEachern confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Janssen	Direct payment for participation in an advisory board on ibrutinib in CLL and MCL. March 2019.	4/10/2019	Direct COI. Janssen markets decitabine for treatment of AML.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Novartis	Direct payment for participation in an advisory board on polycythemia rubra vera and ruxolitinib. March 2019.	4/10/2019	Direct COI. Novartis markets midostaurin for treatment of AML.

Other Notes

Dr. MacEachern's clinical specialty is malignant hematology. She sees and treats patients with AML.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>
Pfizer	Stock (a gift from my grandfather).	I have arranged to be divested from this stock as of January 1, 2018. I have divided it and given as a gift to my nieces and nephews. The total value to each of them is under \$2300	Not a COI. Pfizer is developing glasdegib for treatment of AML in Phase II clinical trial. However, Dr. Michaelis divested this stock before her appointment to the guideline panel.

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Incyte	Steering Committee for registry study or myelofibrosis (see below)	Ongoing	Indirect COI. Incyte is developing LSD1 for treatment of AML in Phase I clinical trial. However, by email on 12/20/17, Dr. Michaelis confirmed that she will not receive direct payment for this activity for the duration of the guideline development process. However, because she will remain involved as an investigator in the registry study, which is funded by Incyte (see Part B, Question 1), this will be considered an indirect COI.
Celgene	Speakers' Bureau	12/20/2017	Not a COI. Celgene markets enasidenib and azacitidine for treatment of AML, and is developing AG-221 for treatment of AML in Phase III clinical trial. However, by email on 12/20/2017, Dr. Michaelis agreed to avoid doing any further paid activities for Celgene for the duration of the guideline development process.
Novartis	Advisory Committee	July 2017, single event	Not a COI. Novartis markets midostaurin for treatment of AML. However, this financial relationship ended before appointment.
TG Therapeutics	Advisory Board	Dec 2017, single event	Not a COI. TG Therapeutics is developing TGR-1202 for treatment of hematologic malignancies, possibly including AML. However,

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			this financial relationship ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Incyte	Registry Study, low-risk myelofibrosis and ET	Local PI, National Steering Committee	Ongoing	Very Indirect COI. Incyte is developing LSD1 for treatment of AML in phase I clinical trial. However, the subject of this research is not relevant to the guideline topic, Dr. Michaelis does not have a leadership role (the study has an overall PI) and all funding goes to her institution.
Bristol-Myers-Squibb	BMS-CA212016; A Phase 1/2, Open-	Local PI	Ongoing	Indirect COI. Bristol-Myers-Squibb is

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	label Randomized Study of Ulocuplumab (BMS-936564) In Combination with Low Dose Cytarabine in Subjects with Newly Diagnosed Acute Myeloid Leukemia			developing nivolumab for treatment of AML in phase II clinical trial and the subject of research is relevant to the guideline topic. However, Dr. Michaelis does not have a leadership role and all funding goes to her institution.
Bioline	BIOLINE-BL-8040-BATTLE; A PHASE IB/II, MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF THE BL-8040 AND ATEZOLIZUMAB COMBINATION FOR MAINTENANCE TREATMENT IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA WHO ARE 60 YEARS OR OLDER- THE BATTLE STUDY	Local PI	Ongoing	Indirect COI. Bioline, in partnership with Genentech, is developing BL-8040 and atezolizumab for treatment of AML in phase I clinical trial. The subject of the research is relevant to the guideline topic. However, Dr. Michaelis does not have a leadership role and all funding goes to her institution.
ASTEX	Astex ASTX727-01: A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with	Local PI	Ongoing	Very Indirect COI. Astex is developing SGE-110 for treatment of AML in phase III clinical trial. However, the subject of the research is not relevant to the guideline topic, Dr. Michaelis does not have a leadership role and all funding goes to her institution.

Company	Description of Research	My Role	End Date	For ASH Internal Use
	Myelodysplastic Syndromes (MDS)			
TG Therapeutics	UTX-TGR-304: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)	Local PI	Fall 2017, Study completed enrollment	Very Indirect COI. TG Therapeutics is developing TGR-1202 for treatment of hematologic malignancies in Phase I clinical trial. TGR-1202 may have applications in AML. However, the subject of the research is not relevant to the guideline topic, Dr. Michaelis does not have a leadership role, and all funding goes to her institution.
Janssen	Janssen 63935937MYF2001: A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor	Local PI	Study on hold but not closed. Ongoing responsibilities	Very Indirect COI. Janssen markets decitabine in the EU for treatment of AML in adults >65. Decitabine is in phase III clinical trial for treatment of AML in the US. However, the subject of the research is not relevant to the guideline topic, Dr. Michaelis does not have a leadership role and all funding goes to her institution.
Pfizer	PFIZER B7861002: A PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS	Local PI	Ongoing	Indirect COI. Pfizer is developing glasdegib for treatment of AML in phase II clinical trials and the subject of the research is relevant to the guideline topic. However, Dr. Michaelis does not have a

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	PF-06747143, ADMINISTERED AS SINGLE AGENT OR IN COMBINATION WITH STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA			leadership role, and all funding goes to her institution.
Celgene	A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy and Safety of CC-486 (oral azacitidine) Alone and in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine	Local PI	Ongoing	Very Indirect COI. Celgene markets enasidenib (US) and azacitidine (EU) for treatment of AML. However, the subject of the research is not relevant to the guideline topic, Dr. Michalis does not have a leadership role, and all funding goes to her institution.
TG-Therapeutics	IIT sponsored by TG-Therapeutics but written by Dr. Savona at Vanderbilt. HEM1538: A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects with Primary Myelofibrosis (PMF), Post- Polycythemia	Local PI. Advisory Committee for Clinical Trial development	Ongoing	Very Indirect COI. TG Therapeutics is developing TGR-1202 for treatment of hematologic malignancies in Phase I clinical trial. TGR-1202 may have applications in AML. However, the subject of this research is not relevant to the guideline topic, Dr. Michaelis does not

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea			have a leadership role, and all funding goes to her institution.
Millennium	Millennium C34002: An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)	Local PI	Ongoing, though study is on hold and may not reopen	Indirect COI. Millennium is also known as Takeda Oncology. Takeda is developing TAK-659 for treatment of AML in phase III clinical trial, and the subject of the research is relevant to the guideline topic. However, Dr. Michaelis does not have a leadership role and all funding goes to her institution.
Incyte	INCB-MA-PV-401: PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES (REVEAL)	Local PI	Ongoing	Very Indirect COI. Incyte is developing LSD1 for treatment of AML in phase I clinical trial. However, the subject of the research is not relevant to the guideline topic, Dr. Michaelis does not have a leadership role, and all funding goes to her institution.
Celator (now owned by JAZZ pharmaceuticals)	Celator 310-206: AN OPEN LABEL PHASE II PHARMACOKINETIC AND PHARMACODYNAMIC	Local PI	Closed Fall of 2017	Not a COI. Jazz pharmaceuticals markets Vyxeos for treatment of AML. However, this clinical

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	ASSESSMENT OF THE POTENTIAL FOR QTC PROLONGATION FOLLOWING FIRST INDUCTION TREATMENT WITH CPX-351 (CYTARABINE:DAUNORUBICIN LIPOSOME INJECTION) IN ACUTE LEUKEMIAS AND MDS PATIENTS			trial ended before Dr. Michaelis's appointment to the guideline panel.
Celator (now owned by JAZZ pharmaceuticals)	Celator0314-208: AN OPEN LABEL PHASE II PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENT OF TREATMENT WITH CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME FOR INJECTION IN ACUTE LEUKEMIAS AND MDS PATIENTS WITH MODERATE HEPATIC IMPAIRMENT	Local PI	Closed Spring of 2017	Not a COI. Jazz pharmaceuticals markets Vyxeos for treatment of AML. However, this clinical trial ended before Dr. Michaelis's appointment to the guideline panel.
Seattle Genetics	SGN33A-005: A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)	Local PI	Closed Aug 2017	Not a COI. Seattle Genetics is developing vadastuximab talirine for treatment of AML in phase III clinical trials. However, this clinical trial ended before Dr. Michaelis's appointment to the guideline panel.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Seattle Genetics	SGN33A-006: A randomized, double-blind, placebo-controlled phase 2 study of vadastuximab talirine (SGN-CD33A) in combination with cytarabine and daunorubicin (7+3) induction chemotherapy in newly-diagnosed acute myeloid leukemia patients	Local PI	Never opened	Not a COI. Seattle Genetics is developing vadastuximab talirine for treatment of AML in phase III clinical trials. However, this clinical trial ended before Dr. Michaelis's appointment to the guideline panel.
ASTEX	Astex SGI-110-04: A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy	Local PI	Study Closed 2016	Not a COI. Astex is developing SGI-110 for treatment of AML in Phase I clinical trial. However, this clinical trial ended before Dr. Michaelis's appointment to the guideline panel.
Janssen	Janssen 63935937MDS3001 (Part 2): A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory	Local PI	Study on hold by sponsor prior to starting enrollment	Indirect COI. Janssen markets decitabine in the EU for treatment of AML in adults >65. Decitabine is in phase III clinical trial for treatment of AML in the US. However, the subject of the research is not relevant to the guideline topic, Dr. Michaelis does not have a leadership role

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	to Erythropoiesis-Stimulating Agent (ESA) Treatment			and all funding goes to her institution.
Pfizer	PFIZER A PHASE 2, DOUBLE-BLIND, RANDOMIZED SAFETY AND EFFICACY STUDY OF PF-04449913 VERSUS PLACEBO WITH DEFINED BEST SUPPORTIVE THERAPY ALLOWED IN BOTH ARMS IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH ONE OR MORE JANUS KINASE INHIBITORS	Local PI	Sponsor closed study after Phase I results released.	Not a COI. Pfizer is developing glasdegib for treatment of AML in phase II clinical trial. However, this clinical trial ended before Dr. Michaelis's appointment to the guideline panel.
CTI	CTI Persist-2 (PAC326): A Randomized Controlled Phase 3 Study of Oral Pacritinib vs Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	Local PI	Closed early 2016	Not a COI. CTI is developing tosedostat for treatment of AML in phase II clinical trial. However, this study ended before Dr. Michaelis's appointment to the guideline panel.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Leukemia and Lymphoma Society	I serve on the development board for the state of Wisconsin. I believe that the LLS gets some contributions through pharmaceutical companies	Unpaid	Ongoing	Not a COI. The Leukemia and Lymphoma Society is a not for profit organization and does not market any drugs or devices used in the treatment of diagnosis of AML.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made? I have written several review articles on the treatment of AML in the elderly population. These articles reflected my medical assessments, not my personal beliefs.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
CTEP/NCI/SWOG	S1612 – Intergroup Study. Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Study Co-Chair	Ongoing
CTEP/NCI/SWOG	S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia	Study Co-Chair	Study closed, publications pending

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain: I frequently give talks to patient groups, to community oncologists on this topic as part of institutional outreach

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My mentor and leadership will be very supportive of my work. My mentorship committee includes Dr. Roy Silverstein, who has encouraged my involvement with ASH. My division is very supportive of my role on this project.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain: Older patients with AML are a key part of my clinical practice.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe: It is possible that I will be invited to additional advisory boards or other pharmaceutical interactions on a professional basis. If I need to decline these invitations, I will be happy to. I did divest from my Pfizer stock in order to participate in this project.

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Medical College of Wisconsin / Jazz Pharmaceuticals	Investigator initiated clinical trial. Study of outpatient treatment of acute leukemia with CPX-351. Dr. Michaelis is the study sponsor and PI.	5/7/2019	Indirect COI. Jazz Pharmaceuticals markets daunorubicin and cytarabine for treatment of AML. The subject of the research is related to the guideline topic and Dr. Michaelis has a leadership role. However, all funding goes to her institution.
Macrogenics	Pharmaceutical-initiated clinical trial of a novel BITE-antibody for newly diagnosed AML. Dr. Michaelis is the local PI.	5/7/2019	Indirect COI. Macrogenics is developing flotetuzumab in Phase I/II clinical trials for treatment of AML. The subject of the research is related to the guideline topic. However, Dr. Michaelis does not have a leadership role and all funding goes to her institution.
Jazz	Investigator initiated clinical trial. Study of treatment of acute leukemia with CPX-351. This study does not explore the effectiveness of CPX-351, but rather the best way to deliver the care.	2/6/2020	Indirect COI. Jazz Pharmaceuticals markets daunorubicin and cytarabine for treatment of AML. The subject of the research is related to the guideline topic and Dr. Michaelis has a leadership role.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			However, all funding goes to her institution.
Jazz Pharmaceuticals	Transfers of value for education and food and beverage (2018)	2/21/2020	Direct COI. Jazz Pharmaceuticals markets daunorubicin and cytarabine for treatment of AML. This disclosure was made after the recommendations were formed.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/28/2017; Kunkle 1/3/2018	No	Yes	Dr. Michaelis reports <i>previous</i> direct financial relationships with companies that market treatments for AML (Celgene, Novartis). She agrees to avoid such direct conflicts during the guideline development process. She is currently involved in research projects funded by companies that market or are developing treatments for AML, including Incyte, Bristol-Myers-Squibb, Bioline, Astex, TG Therapeutics, Janssen, Pfizer and Millennium. She does not have a leadership role on these projects. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 5/20/2019	No	Yes	New disclosures. See Part D. On 5/20/2019, Dr. Michaelis confirmed all information in this form.
Alexander 2/14/2020	No	Yes	New disclosure. See Part D. On 2/6/2020, Dr. Michaelis confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Michaelis has a leadership role (study co-chair) on two research studies on AML funded by Cancer Therapy Evaluation Program/National Cancer Institute/SWOG: (1) azacitidine with or without nivolumab vs. midostaurin or decitabine and cytarabine alone in older patients with previously untreated AML or high-risk MDS (study ongoing) and (2) idarubicin, cytarabine, and pravastatin in patients with relapsed AML (study closed, publications pending). She has authored review articles about the treatment of AML in older adults, and she gives frequent talks on the topic as part of her institution's community outreach. Dr. Michaelis is a hematologist/oncologist who sees and treats patients with AML.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
AAMDSIF & Cleveland Clinic ASH Friday Satellite Symposium, December 2017	Activity co-director and chaired the symposium	December 8, 2017	Not a COI. Aplastic Anemia and MDS International Foundation and the Cleveland Clinic are non-profit organizations.
Bristol Myers Squibb	Speaker	October 3, 2017	Not a COI. Bristol Myers Squibb is developing nivolumab for treatment of AML in phase II clinical trial. However, this paid activity ended before Dr. Mukherjee’s appointment to the guideline panel.
Bristol Myers Squibb	Speaker	August 1, 2017	Not a COI. Bristol Myers Squibb is developing nivolumab for treatment of AML in phase II clinical trial. However, this paid activity ended before Dr. Mukherjee’s appointment to the guideline panel.
Takeda	Advisory Committee or Board	May 5, 2017	Not a COI. Takeda oncology is developing TAK-659 for treatment of AML in Phase III clinical trial. However, this paid activity ended before Dr. Mukherjee’s appointment to the guideline panel.
AAMDSIF & Cleveland Clinic ASH Friday	Activity co-director and chaired the symposium	December 2, 2016	Not a COI. Aplastic Anemia and MDS

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Satellite Symposium, December 2016			International Foundation and the Cleveland Clinic are non-profit organizations.
Pfizer	Honoraria	November 17, 2016	Not a COI. Pfizer is developing glasdegib for treatment of AML in phase II clinical trial. However, this paid activity ended before Dr. Mukherjee's appointment to the guideline panel.
Projects in Knowledge	Honoraria	August 31, 2016	Not a COI. Projects in Knowledge is an ACCME-accredited medical education company that provides CME to physicians.
Novartis	Advisory Committee or Board	July 15, 2016	Not a COI. Novartis markets midostaurin for treatment of AML. However, this paid activity ended before Dr. Mukherjee's appointment to the guideline panel.
Projects in Knowledge	Honoraria	February 29, 2016	Not a COI. Projects in Knowledge is an ACCME-accredited medical education company that provides CME to physicians.
Novartis	Consultancy	February 16, 2016	Not a COI. Novartis markets midostaurin for treatment of AML. However, this paid activity ended before Dr. Mukherjee's appointment to the guideline panel.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Novartis (Providing study drug and research related patient expenses). No salary support or any other reimbursements	Investigator Initiated Study (NCT02071901) – Eltrombopag Olamine in Improving Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Chemotherapy	PI	Ongoing (expected completion date – December , 2018)	Indirect COI. Novartis markets midostaurin for treatment of AML. The subject of this research project, for which Dr. Mukherjee has a leadership role, is relevant to the guideline topic; however, the guidelines are unlikely to address platelet count recovery specifically. All funding goes to his institution.
Celgene	Non-therapeutic Investigator Initiated Study (NCT02863458) –	PI	Ongoing	Indirect COI. Celgene markets azacitidine for treatment of AML and enasidenib for treatment of relapsed or

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	DNA Hypomethylating Agents and Lenalidomide in Elderly Patients with Myeloid Malignancies in the US (an epidemiological study using Medicare files)			refractory AML and is exploring the use of lenalidomide for AML. The subject of this research is relevant to the guideline topic, and Dr. Mukherjee has a leadership role. All funding goes to his institution.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Acute Myeloid Leukemia in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain: **The only way I generate revenue for my institution is by seeing and treating inpatient and outpatient leukemia patients. I am also a part of teaching faculty involved in teaching hematology-oncology fellows and medical residents.**

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution? **I will receive excellent support from both my mentor and my institution. This is consistent with my institutional policy that has always encouraged strong participation by hematologic malignancy faculty in ASH scientific, educational and volunteer activities.**

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
 Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
 Yes

If yes, please explain: **We routinely discuss clinical trial participation for older AML patients at the Cleveland Clinic as this is a clinical trial heavy program.**

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
 Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Novartis	Direct payment for participation on an advisory board: Cardiovascular effects of tyrosine kinase inhibitors in Chronic Myeloid Leukemia patients. September 28-29, 2018	11/2018	Direct COI. Novartis markets midostaurin for the treatment of AML.
Celgene/Acceleron	Direct payment for participation on an advisory board on MDS. October 20, 2018	11/2018	Direct COI. Celgene markets azacitidine for treatment of AML.
Partnership for Health Analytic Research, LLC (PHAR, LLC)	Direct payment for consulting. October 31, 2018. This was consultation done to compare application of different oncology value based framework tools between ASCO value framework, NCCN evidence blocks and Institute for Clinical and Economic Review (ICER) methodology.	5/7/2019	Not a COI. Partnership for Health Analytic Research, LLC is a health research consulting firm and does not market any products or devices used in the diagnosis or treatment of AML. They would not be affected by recommendations made by the guideline panel.
McGraw Hill Hematology Oncology Board Review	Hematology Oncology Board Review December, 2018 – My role is editing questions submitted by various authors for the online question bank. Will complete in June, 2019.	5/7/2019	Not a COI. McGraw Hill is a science education and publishing company and would not be affected by recommendations made by the guideline panel.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Novartis	Direct payment for participation in an advisory board. Jan 17th, 2019 and March 8-9, 2019 – As a panelist surveying the treatment practices of chronic myeloid leukemia (CML) in the US and Europe.	5/7/2019	Direct COI. Novartis markets midostaurin for the treatment of AML.
Celgene	Direct payment for consulting. Health Economics and Outcomes Research (HEOR) on treatment patterns of low-risk MDS in the US, November 5, 2018 – This is a consultancy to help with algorithms to extract and analyze treatment and outcomes data on low-risk myelodysplastic syndromes (MDS) using health claims based dataset (Optum dataset). Will complete in June of 2019.	5/7/2019	Direct COI. Celgene markets azacitidine for treatment of AML.
Aplastic Anemia and MDS International Foundation	Feb 28th, 2019 – Webinar speaker on "What's New in MDS? Important Updates from ASH 2018"	5/7/2019	Not a COI. The Aplastic Anemia and MDS International Foundation is a not for profit organization whose mission is to support patients living with bone marrow failure diseases. They would not be affected by recommendations made by the guidelines.
EUSA Pharmaceuticals	Direct payment for health outcomes	11/14/2019	Not a COI. EUSA pharmaceutical does

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	research for Castleman’s disease using claimed base dataset and SEER.		not market any devices or drugs used in the diagnosis or treatment of AML.
Bristol Myers Squibb	Research funding as a PI in Maximum Tolerated Dose Study Japan Global expansion. This study closed on October 2,2019.	2/12/2020	Indirect COI. Bristol Myers Squibb is developing nivolumab for treatment of AML in phase II clinical trial.
Novartis	Direct payment for consultancy, travel and lodging, and food and beverages (March 2018 to September 2018).	2/12/2020	Direct COI. Novartis markets midostaurin for the treatment of AML.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 1/12/2018; Kunkle 1/12/2018	No	Yes	<p>Dr. Mukherjee reports recent financial relationships with companies that could be affected by the guidelines (Novartis, Takeda, Bristol Myers Squibb). As a condition of his appointment, he has agreed to avoid direct financial conflicts such as these for the duration of the guideline development process.</p> <p>Dr. Mukherjee has leadership roles on research that is funded by Celgene and Novartis. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.</p>
Alexander 4/12/2019	Yes	Yes	<p>New disclosures. See Part D.</p> <p>Dr. Mukherjee reports direct financial relationships with companies that market treatments for AML (Novartis, Celgene). Recusal will be required.</p>
Alexander 5/20/2019	Yes	Yes	<p>New disclosures. See Part D.</p> <p>Dr. Mukherjee reports direct financial relationships with companies that market treatments for AML (Novartis, Celgene). Recusal will be required.</p>
Alexander 1/26/2020	Yes	Yes	On 1/26/2020, Dr. Mukherjee confirmed all information in this form.
Alexander 2/28/2020	Yes	Yes	New disclosures. See Part D. On 2/28/2020, Dr. Mukherjee confirmed these disclosures are correct.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Novartis	Direct payment for participation on an advisory board: Cardiovascular effects of tyrosine kinase inhibitors in Chronic Myeloid Leukemia patients. September 28-29, 2018	11/2018	Direct COI. Novartis markets midostaurin for the treatment of AML.
Celgene/Acceleron	Direct payment for participation on an advisory board on MDS. October 20, 2018	11/2018	Direct COI. Celgene markets azacitidine for treatment of AML.
Novartis	Direct payment for participation in an advisory board. Jan 17th, 2019 and March 8-9, 2019 – As a panelist surveying the treatment practices of chronic myeloid leukemia (CML) in the US and Europe.	5/7/2019	Direct COI. Novartis markets midostaurin for the treatment of AML.
Celgene	Direct payment for consulting. Health Economics and Outcomes Research (HEOR) on treatment patterns of low-risk MDS in the US, November 5, 2018 – This is a consultancy to help with algorithms to help with algorithms to extract and analyze treatment and outcomes data on low-risk myelodysplastic syndromes (MDS) using health claims based dataset (Optum dataset). Will complete in June of 2019.	5/7/2019	Direct COI. Celgene markets azacitidine for treatment of AML.

Other Notes

Dr. Mukherjee sees and treats patients with leukemias at the Cleveland Clinic. He reports that he routinely discusses clinical trial participation for older adults with AML.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Kite Pharma	Clinical trial for ALL, Car-T therapy for relapsed/refractory ALL	Site PI	Ongoing	Indirect COI. Kite Pharma is not currently developing any drugs or products used in the treatment or diagnosis of AML, but Kite is owned by Gilead, who is developing entospletinib in Phase I/II clinical trials for treatment of AML. However, the subject of the research is not related to the guideline topic, Dr. O'Dwyer does not have a leadership role, and all funding goes to her institution.
Aptos	Phase Ib clinical trial for use of APTO-253 in relapsed/refractory AML	Site PI	Ongoing	Indirect COI. Aptos is developing APTO-253 in Phase I clinical trials for treatment of AML. The subject of the research is related to the guideline topic. However, Dr. O'Dwyer does not have a leadership role and all funding goes to her institution.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Acute Myeloid Leukemia in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

My primary specialty is hematologic malignancies, specifically acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative disorders.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain: I am a clinician who cares for and treats patients with acute myeloid leukemia, including patients older than 60 years.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Pfizer	Indirect payment to institution for phase 3 study on adult patients with ALL.	2/12/2020	This activity was reported on open payments. On 2/19/2020, Dr. O'Dwyer confirmed that this is an error, and her institution did not receive money from Pfizer for this study in 2018.
Pfizer	Direct payments for education in 2018.	2/12/2020	This activity was reported on open payments. On 2/19/2020, Dr. O'Dwyer confirmed that this is an error, and that she did not receive any direct payments from Pfizer.
Foundation Medicine, Inc	Direct payment for food and beverage in 2018.	2/12/2020	This activity was reported on open payments. On 2/19/2020, Dr. O'Dwyer confirmed that this is an error, and that she did not receive any direct payments from Foundation Medicine, Inc.
Jazz Pharmaceuticals Inc.	Direct payment for food and beverage in 2018.	2/12/2020	Not a COI. This activity ended before Dr. O'Dwyer was appointed to the guideline panel.
Kite Pharma, Inc.	Direct payment for food and beverage in 2018.	2/12/2020	Not a COI. This activity ended before Dr. O'Dwyer was appointed to the guideline panel.
Shire North American Group Inc	Direct payment for food and beverage in 2018.	2/12/2020	Not a COI. This activity ended before Dr. O'Dwyer was appointed to the guideline panel.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander 6/27/2019; Hicks 6/27/2019	No	Yes	Dr. O'Dwyer reports research funding from companies that are developing treatment for AML (Kite Pharma, Aptos). These indirect conflicts will be managed through disclosure and panel composition. As a condition of her appointment, Dr. O'Dwyer agrees avoid participating in any advisory boards, consulting, branded or non-branded talks, speaker's bureaus and to avoid any direct transfers of value from any pharmaceutical company.
Alexander 2/3/2020	No	Yes	On 1/10/2020, Dr. O'Dwyer confirmed all information in this form.
Alexander 2/18/2020	No	Yes	New disclosures. See Part D. On 2/19/2020, Dr. O'Dwyer confirmed these new disclosures.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

--



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Janssen	Study on multiple myeloma	Site-PI	8/2015	Not a COI. Janssen markets decitabine for treatment of patients >65 years with acute myeloid leukemia in the EU. Decitabine is in phase III clinical trial in the US. However, this study ended before Dr. Rosko’s appointment to the guideline panel.
Acetylon	Study on multiple myeloma	Site-PI	2014	Not a COI. Acetylon was acquired by Celgene in 2016. Celgene markets enasidenib and azacitidine for treatment of AML. However, this study ended before Dr. Rosko’s appointment to the guideline panel.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in older adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: My research and clinical practice is focused on the improvement of outcomes of older adults with blood cancer

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made? Reviews

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Institutions / mentors are supportive

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Geriatric hematology, multiple myeloma

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Takeda	Research funding. Site PI for study on multiple myeloma.	10/23/2018	Indirect COI. Takeda is developing Takeda 659 for treatment of AML in phase III clinical trials. However, the subject of this research is not related to AML, Dr. Rosko does not have a leadership role, and all funding goes to her institution.
AbbVie	Research funding. Site PI for study on multiple myeloma.	10/23/2018	Very Indirect COI. AbbVie markets venetoclax for treatment of AML in older adults. However, the subject of this research is not related to AML, Dr. Rosko does not have a leadership role, and all funding goes to her institution.
Jazz Pharmaceuticals	Unpaid advisory board. Jazz Pharmaceuticals provided travel and hotel support.	4/28/2019	Direct COI. Jazz markets Vyxeos (daunorubicin and cytarabine) for treatment of AML in adults with newly diagnosed t-AML or AML-MRC.
Millennium Pharmaceuticals (Takeda Oncology)	Research funding for Vyxeos. Site PI.	4/28/2019	Indirect COI. Millennium Pharmaceuticals is owned by Takeda Oncology, who is developing pevonedistat for

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			treatment of AML and the subject of the research is related to AML. However, Dr. Rosko does not have a leadership role and all funding goes to her institution.
Janssen	Research funding for study on older adult multiple myeloma patients. Site PI.	4/28/2019	Very Indirect COI. Janssen markets decitabine for the treatment of AML. However, the subject of the research is unrelated to AML, Dr. Rosko does not have a leadership role, and all funding goes to her institution.
Regeneron	REGN5458 a Phase 1 -2 study for patients with relapsed/refractory Multiple Myeloma. Site PI.	10/3/2019	Regeneron does not currently market any drugs or devices used in the diagnosis or treatment of AML.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 12/12/2017; Kunkle 1/3/2018	No	No	Dr. Rosko has no current conflicts of interest with for-profit companies that could be affected by the guidelines.
Alexander 11/11/2018	No	Yes	New disclosures. See Part D. Dr. Rosko reports research funding from companies that market or are developing drugs to treat AML (AbbVie, Takeda). These indirect financial relationships will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 5/20/2019	Yes	Yes	New disclosures. See Part D. Dr. Rosko reports research funding from companies that market drugs to treat AML (Janssen, Millennium Pharmaceuticals). These indirect financial relationships will be managed through disclosure and panel composition. Dr. Rosko has a new direct financial relationship with Millennium Pharmaceuticals, Inc (Takeda Oncology) who is developing drugs to treat AML. This direct financial relationship will be managed through recusal.
Alexander 10/9/2019	Yes	Yes	New disclosure. See Part D.
Alexander 2/3/2020	Yes	Yes	On 1/12/2020, Dr. Rosko confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Millennium Pharmaceuticals (Takeda Oncology)	Unpaid advisory board. Millennium Pharmaceuticals provided travel and hotel support.	4/28/2019	Direct COI. Millennium Pharmaceuticals is owned by Takeda Oncology, who is developing pevonedistat in Phase III clinical trials for treatment of AML.

Other Notes

Dr. Rosko reports previously published reviews on AML. As a geriatric oncologist she sees and treats older adults with AML. She reports that her research and clinical practice is focused on improving outcomes of older adults with blood cancer.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Celgene Corp	Advisory Board	05/2017	Not a COI. This financial relationship ended prior to Dr. Sekeres’ appointment as chair of the guideline panel. As a condition of his appointment, Dr. Sekeres has agreed to avoid direct financial conflicts of interest for the duration of the guideline development process, including future paid activities for this company.
Opsona	DSMB	Ongoing	Not a COI. Opsona does not market any products or devices related to the treatment of acute myeloid leukemia.
Tolero	DSMB	9/2017	Not a COI. Tolero is developing Alvocidib for treatment of AML in Phase II studies. However, this financial relationship ended before appointment. As a condition of his appointment, Dr. Sekeres has agreed to avoid direct financial conflicts of interest for the duration of the guideline development process, including future paid activities for this company.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Celgene Corporation	Clinical trial on myelodysplastic syndromes	Sub-PI	Ongoing	Very Indirect COI. Celgene markets azacitidine and enasidenib for treatment of AML, and is developing AG-221 in phase III clinical trial for treatment of AML. However, the subject of the research is not relevant to the guideline topic and Dr. Sekeres does not have a leadership role. Furthermore, all funding goes to his institution.
Takeda	Clinical trial on myelodysplastic syndromes	Sub-PI	06/2017	Very Indirect COI. Takeda is developing TAK-659 for treatment of AML in Phase II clinical trials. However, the

Company	Description of Research	My Role	End Date	For ASH Internal Use
				subject of the research is not relevant to the guideline topic, Dr. Sekeres does not have a leadership role, and all funding goes to his institution.
Syros	Clinical trial on myelodysplastic syndromes	Sub-PI	Ongoing	Very Indirect COI. Syros is developing SY-1425 for treatment of AML in Phase II clinical trial. However, the subject of the research is not relevant to the guideline topic, Dr. Sekeres does not have a leadership role and all funding goes to his institution.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would have full academic freedom to express views/make recommendations.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Myeloid malignancies

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I care for older adults with AML.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Amgen Inc	Indirect payments for phase 2 research study Thrombocytopenia in MDS.	2/5/2020 (Open Payments)	On 2/18/22020, Dr. Sekeres confirmed that this information is incorrect.
Celgene Corp	Direct payments for travel and lodging, food and beverage, and consulting fees.	2/5/2020 (Open Payments)	On 2/18/22020, Dr. Sekeres confirmed that this information is incorrect.
Pfizer	Direct payments for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	2/5/2020 (Open Payments)	On 2/18/22020, Dr. Sekeres confirmed that this information is incorrect.
Takeda	Direct payments for food and beverage and consulting fee.	2/5/2020 (Open Payments)	On 2/18/22020, Dr. Sekeres confirmed that this information is incorrect.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 10/15/17; Kunkle 1/3/2018	No	Yes	Dr. Sekeres has a <i>previous</i> direct financial relationship with a company that is developing a treatment for AML (Tolero). As a condition of his appointment, he has agreed to avoid all direct financial conflicts of interest during the guideline development process. He is currently involved in research projects funded by companies that market treatments for AML, including Celgene, Takeda and Syros. None of the research projects are relevant to the guideline topic, Dr. Sekeres does not have any leadership roles, and all funding goes to his institution. These very indirect conflicts will be managed through disclosure, panel composition, and by including a co-chair who does not have conflicts. If Dr. Sekeres has an indirect conflict relevant to a guideline question or recommendation, the co-chair will assume the chair role.
Alexander 5/20/2019	No	Yes	On 4/16/2019, Dr. Sekeres confirmed all information in this form.
Alexander 2/3/2020	No	Yes	On 1/14/2020, Dr. Sekeres confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Sekeres is a hematologist in active clinical practice who specializes in myeloid malignancies, including care of older adults with AML.



ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Abbvie	Consultant	1/31/17	Not a COI. Abbvie markets venetoclax for treatment of AML in older adults. However, this paid activity ended before Dr. Stone’s appointment to the guideline panel.
Actinium	Board Member and Advisory Committee	12/31/18	Indirect COI. Actinium is developing iomab-B CD45 in phase III trial for treatment of AML in patients >55 with relapsed or refractory AML. However, this is out of scope for these guidelines.
Agios	Consultant	12/31/18	Direct COI. Agios is developing AG-221 in phase III clinical trial for treatment of AML.
Amgen	Consultant	12/31/17	Not a COI. Amgen is developing AMG 330 for treatment of AML in phase I clinical trial. However, this paid activity ended before Dr. Stone’s appointment to the guideline panel.
Argenx	Consultant	12/31/18	Indirect COI. Argenx is developing ARGX 110 for treatment of AML in phase I/II clinical trials.
Arog	Consultant	12/31/18	Direct COI. Arog is developing crenolanib for treatment of AML in phase III clinical trial.
Astellas	Consultant	12/31/18	Indirect COI. Astellas markets gilteritinib for treatment of relapsed/refractory AML. Relapsed or refractory AML is out of scope for these guidelines, but gilteritinib could be indirectly affected by recommendations about treatment.
Celator	Consultant	12/31/16	Not a COI. Celator is a subsidiary of Jazz Pharmaceuticals. Jazz markets

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			daunorubicin and cytarabine for treatment of AML. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Celgene	Consultant	12/31/18	Direct COI. Celgene markets enasidenib for treatment of relapsed or refractory AML.
Cornerstone	Consultant	12/31/18	Indirect COI. Cornerstone Pharmaceuticals is developing CPI-613 for treatment of AML in phase II clinical trial. Although CPI-613 is not yet to market, it could be indirectly affected by recommendations made about treatment of AML.
Fujifilm	Consultant	12/31/17	Not a COI. FujiFilm pharmaceuticals is developing FF-10101-01 for treatment of AML in phase I clinical trial. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Janssen	Consultant	12/31/17	Not a COI. Janssen markets decitabine for treatment of AML in the EU. Decitabine is in phase III clinical trial for treatment of AML in the US. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Jazz	Consultant	12/31/17	Not a COI. Jazz Pharmaceuticals markets daunorubicin and cytarabine for treatment of AML. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Juno	Consultant	12/31/16	Not a COI. Juno is developing JTCR016 for treatment of AML in phase I/II clinical trials. However, this paid activity ended before Dr.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			Stone's appointment to the guideline panel.
Karyopharm	Consultant	12/31/16	Not a COI. Karyopharm Therapeutics is developing KPT-330 for treatment of AML in phase II clinical trial. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Merck	Consultant	12/31/16	Not a COI. Merck, in partnership with Mitsubishi Tenabe, is developing OTX-015 (a BET inhibitor) for treatment of AML in phase I clinical trial. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Novartis	Consultant/Research Funding	12/31/17	Not a COI. Novartis markets midostaurin for treatment of AML. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Ono	Consultant	6/30/16	Not a COI. Ono is developing ONO-7475 for treatment of AML in phase I clinical trial. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Orsenix	Consultant	12/31/17	Not a COI. Orsenix is developing ORH-2014 for treatment of AML in phase I clinical trial. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.
Otsuka	Consultant	12/31/17	Not a COI. In partnership with Janssen, Otsuka is developing decitabine in phase III clinical trial for treatment of AML in the US. Decitabine is approved for treatment of AML in the EU. However, this paid activity ended

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			before Dr. Stone's appointment to the guideline panel.
Pfizer	Consultant	12/31/17	Not a COI. Pfizer is developing glasdegib for treatment of AML in phase II clinical trial. However, this paid activity ended before Dr. Stone's appointment to the guideline panel.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Novartis	Research Funding for AML drug	Principal Investigator	12/31/17	Not a COI. Novartis markets midostaurin for treatment of AML and Dr. Stone had a leadership role in the project. However, this research ended before Dr. Stone’s appointment to the guideline panel.
Agios	Research Funding for AML Drug	Local Principal Investigator	12/31/18	Indirect COI. Agios is developing AG-221 for treatment of AML in phase III clinical trial and the subject of the research is relevant to the guideline topic. However, Dr. Stone does not have a leadership

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				role and all funding goes to his institution.
Arog	Research Funding for AML Drug	Local Principal Investigator	12/31/18	Indirect COI. Arog is developing crenolanib for treatment of AML in phase III clinical trial and the subject of the research is relevant to the guideline topic. However, Dr. Stone does not have a leadership role and all funding goes to his institution.
Genus	Research Funding for AML Drug	Local Principal Investigator	12/31/18	Indirect COI. Genus is developing G0-203 for treatment of AML in phase II clinical trial and the subject of the research is relevant to the guideline topic. However, Dr. Stone does not have a leadership role and all funding goes to his institution.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Prime Oncology	Faculty Presenter	Paid	2018	Not a COI. Prime Oncology is an ACCME-accredited medical education company that provides CME to physicians.
PER Year in Review	Faculty Presenter	Paid	2018	Physicians Education Resource is an ACCME-accredited medical education company that provides CME to physicians.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AML in Older Adults

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made? Have given multiple lectures and written extensively on AML therapy. No particular viewpoints. Please see CV. Please see enclosed recent AML lecture.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution? Not applicable

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

Clinical Practice

9. Do you see patients clinically?

- No
- Yes

If yes, what is your primary specialty or subspecialty? Hematological malignancies and related disorders.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
- Yes

If yes, please explain: Obviously, my practice in AML could be effected by guidelines.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
- Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
AbbVie	Direct payment for consulting	11/11/2018	Direct COI. AbbVie markets venetoclax for treatment of AML in older adults.
Actinium	Direct payment for advisory board	11/11/2018	Indirect COI. Actinium is developing iomab-B DC45 in phase III clinical trials for treatment of AML in patients >55 with relapsed of refractory AML. However, these guidelines will not address patients with relapsed or refractory AML.
Argenix	Direct payment for data safety and monitoring board	11/11/2018	Indirect COI. Argenx is developing ARGX 110 for treatment of AML in phase I/II clinical trials.
Arog	Direct payment for consulting	11/11/2018	Direct COI. Arog is developing crenolanib for treatment of AML in phase III clinical trial.
AstraZeneca	Direct payment for one time advisory board participation. October 2018.	11/11/2018	Direct COI. AstraZeneca partners with Otsuka to market decitabine for treatment of AML.
Celgene	Direct payment for consulting, data safety and monitoring board, steering committee.	11/11/2018	Direct COI. Celgene markets azacitidine for treatment of AML.
Cornerstone	Direct payment for consulting. The correct end date for this activity is 12/31/2017.		Not a COI. This is an update to Part A. This activity is no longer a direct COI, because it ended prior to Dr. Stone's appointment to the guideline panel.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Jazz	Direct payment for consulting	11/11/2018	Direct COI. Jazz markets daunorubicin and cytarabine for treatment of AML.
Macrogenics	Direct payment for participation on advisory board. Spring 2018.	11/11/2018	Indirect COI. Macrogenics is developing flotetuzumab for treatment of AML in phase I clinical trials.
Novartis	Direct payment for consulting. Ended November 2018.	11/11/2018.	Direct COI. Novartis markets midostaurin for treatment of AML.
Sumitomo	Direct payment for participation on advisory board. Ended 2017.	11/11/2018	Not a COI. This activity ended prior to appointment.
AbbVie	Institutional research funding for AML drug. Dr. Stone is the local PI.	11/11/2018	Indirect COI. AbbVie markets venetoclax for treatment of AML in older adults and the research is related to the guideline topic. However, Dr. Stone does not have a leadership role and all funding goes to his institution.
Takeda	Direct payment for participation on data safety and monitoring board	11/11/2018	Direct COI. Takeda is developing TAK-650 for treatment of AML in phase III clinical trials.
AbbVie	Direct payment for consulting. This activity will end on 6/1/2019.	5/1/2019	Direct COI. Abbvie markets venetoclax for the treatment of AML in older adults.
Actinium	Direct payment. Board member and advisory committee. This activity is ongoing.	5/1/2019	Indirect COI. Actinium is developing iomab-B CD45 for treatment of AML in patients over 55 with relapsed or refractory AML. Relapsed or refractory AML is out of scope for these guidelines.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Amgen	Direct payment for consulting. This activity ended 5/3/2019.	5/1/2019	Indirect COI. Amgen is developing AMG 330 in Phase I clinical trials for treatment of AML.
Argenx	Direct payment for service on data safety and monitoring board. This activity is ongoing.	5/1/2019	Indirect COI. Argenx is developing ARGX 110 for treatment of AML in phase I/II clinical trials.
Astellas	Direct payment for consulting. This activity ended on 4/30/2019.	5/1/2019	Indirect COI. Astellas markets gilteritinib for treatment of relapsed/refractory AML. Relapsed or refractory AML is out of scope for these guidelines, but gilteritinib could be indirectly affected by recommendations about treatment, for example, if it is approved for treatment of initial AML.
Cornerstone	Consultant. Dr. Stone clarified that this activity ended on 6/1/2017, no 12/31/2018 as previously stated. This is no longer an indirect COI.	5/1/2019	Not a COI. This activity ended before Dr. Stone's appointment to the guideline panel. This is an update to Part A, Question 4.
Jazz Pharmaceuticals	Direct payment for consulting. This activity ended 12/31/2018	5/1/2019	Direct COI. Jazz Pharmaceuticals markets daunorubicin and cytarabine for treatment of AML
Novartis	Direct payment for consulting. This activity ended 12/31/2018.	5/1/2019	Direct COI. Novartis markets midostaurin for treatment of AML.
Pfizer	Direct payment for consulting. This activity ended 12/31/2018.	5/1/2019	Direct COI. Pfizer markets glasdegib for treatment of AML in older adults for whom intensive

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			chemotherapy is not an option.
AstraZeneca	Direct payment for consulting. This activity ended 11/30/2018.	5/1/2019	Indirect COI. AstraZeneca is develop AZD1208 in Phase I clinical trials for treatment of AML.
Macrogenics	Direct payment for consulting. This activity ended 7/31/2018	5/1/2019	Indirect COI. Macrogenics is developing flotetuzumab for treatment of AML in phase I clinical trials.
Stemline Therapeutics	Direct payment for consulting. This activity ended 12/31/2018.	5/1/2019	Indirect COI. Stemline Therapeutics is developing TAGRAXOFUSP (SL-401) in phase II clinical trial for treatment of AML.
Takeda	Direct payment for serving on a data safety and monitoring board.	5/1/2019	Direct COI. Takeda is developing pevonedistat in phase III clinical trials for treatment of AML.
Daiichi Sankyo	Direct payment for consulting. This activity ended on 4/30/2019	5/1/2019	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for treatment of AML.
Abbvie	Research funding for costs related to investigator initiated trial on AML.	5/1/2019	Indirect COI. AbbVie markets venetoclax for treatment of AML. However, Dr. Stone does not have a leadership role and all funding goes to his institution.
AROG	This research activity is ongoing.	5/1/2019	This is an update to Part B, Question 1.
PRIME	Direct payment for speaking (faculty presentation)	5/1/2019	Not a COI. PRIME is an ACCME accredited provider of continuing medical education (CME).
PER	Direct payment for speaking (faculty presentation)	5/1/2019	Not a COI. PER is an ACCME accredited provider of continuing medical education (CME).

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Research-to-Practice	Direct payment for speaking (faculty presentation)	5/1/2019	Not a COI. Research to Practice is an ACCME accredited provider of continuing medical education (CME).
Dava Oncology	Direct payment for speaking (faculty presentation)	5/1/2019	Indirect COI. Dava Oncology does not market or develop any products or drugs used in the diagnosis or treatment of AML. However, they do provide services to pharmaceutical companies, including identifying participants for advisory boards and consulting positions.
Bioline	Direct payment for participation on an advisory board	5/1/2019	Indirect COI. Bioline is developing products to be used in bone marrow transplants, which is a treatment option for AML. However, transplants are out of scope for this guidelines.
Trovagene	Direct payment for participation on advisory board.	5/1/2019	Indirect COI. Trovagene is developing onvansertib in phase II clinical trial for treatment of AML.
AbbVie	Direct payment for participation on a steering committee	2/5/2020	Direct COI. Abbvie is developing venetoclax in phase III clinical trials for treatment of AML in older adults.
Agios	Direct payment for participation on a steering committee	2/5/2020	Direct COI. Agios is developing AG-221 in phase III clinical trial for treatment of AML.
Gemoab	Direct payment for participation on an advisory board. December 2019.	2/5/2020	Indirect COI. Gemoab is developing GEM333 in phase I clinical trial for treatment of relapsed/refractory AML.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Janssen	Direct payment for participation on an advisory board. December 2019.	2/5/2020	Direct COI. Janssen markets decitabine for treatment of AML.
Takeda	Direct payment for participation on an advisory board. October 2019.	2/5/2020	Direct COI. Takeda is developing pevonedistat in phase III clinical trials for treatment of AML.
Celgene	Research funding through institution for studies AZA-AML-001 and AG-221-AML-005.		Indirect COI. Celgene markets azacitidine for treatment of AML.
Novartis	Research funding through institution for research related publication support.		Indirect COI. Novartis markets midostaurin for treatment of AML.
AbbVie	Research funding for study A16-262.		Indirect COI. AbbVie markets venetoclax for treatment of AML in older adults.
Novartis	Research funding for A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF INDUCTION DAUNORUBICIN AND OR CYTARABINE AND CONSOLIDATION HIGH DOSE CYTARABINE CHEMOTHERAPY PLUS MIDOSTAURIN PKC412IND NUMBER 101261 OR PLACEBO IN NEWLY DIAGNOSED PATIENTS LESS THAN 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA AML.		Indirect COI. Novartis markets midostaurin for treatment of AML and the subject of the research is related to the guideline topic. However, Dr. Stone does not have a leadership role and all funding goes to his institution.
Otsuka	Consultancy		Direct COI. In partnership with Janssen, Otsuka is developing decitabine in

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			phase III clinical trial for treatment of AML in the US. Decitabine is approved for treatment of AML in the EU.
Sun Pharmaceutical Industries, Inc.	Direct payments for transfer of value of food and beverage.		
Zimmer Biomet Holdings, Inc	Direct payments for transfer of value of food and beverage and travel and lodging.		Not a COI. Zimmer Biomet Holdings does not market any devices or drugs used in the diagnosis or treatment of AML.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Acute Myeloid Leukemia in Older Adults
----------------------------	---

Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Alexander, 1/18/2018	Yes	Yes	<p>Dr. Stone has direct financial conflicts with companies that market or are developing therapies for AML and therefore could be affected by these guidelines, including Actinium, Agios, Arog, Astellas and Celgene (see summary below). Recusal will be required for these conflicts if they are specific to any recommendation.</p> <p>Dr. Stone is also involved in research projects specific to AML treatment that are funded by Agios, Arog and Genus. He does not have a leadership role and all funding goes to his institution. These indirect conflicts will be managed through disclosure and panel composition.</p>
Alexander 11/11/2018	Yes	Yes	<p>New disclosures. See Part D.</p> <p>The scope of these guidelines does not include patients with relapsed or refractory AML. Some decisions regarding direct conflicts were made before the scope of the guidelines was defined. These changes are reflected in the summary of conflicts below but may not be correct in earlier sections of the form.</p>
Alexander 5/20/2019	Yes	Yes	New disclosures. See Part D.
Alexander 2/18/2020	Yes	Yes	New disclosures. See Part D.
Alexander 3/3/2020	Yes	Yes	On 3/3/2020, Dr. Stone confirmed all information in this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Agios	Personal income for consulting	01/09/2018	Direct COI. Agios is developing AG-221 in phase III clinical trial for treatment of AML.
Arog	Personal income for consulting	01/09/2018	Direct COI. Arog is developing crenolanib for treatment of AML in phase III clinical trial.
Celgene	Personal income for consulting	01/09/2018	Direct COI. Celgene markets enasidenib for treatment of relapsed or refractory AML.
AbbVie	Direct payment for consulting	11/11/2018	Direct COI. AbbVie markets venetoclax for treatment of AML in older adults.
AstraZeneca	Direct payment for one-time advisory board participation. October 2018.	11/11/2018	Direct COI. AstraZeneca partners with Otsuka to market decitabine for treatment of AML.
Jazz	Direct payment for consulting	11/11/2018	Direct COI. Jazz markets daunorubicin and cytarabine for treatment of AML.
Novartis	Direct payment for consulting. Ended November 2018.	11/11/2018.	Direct COI. Novartis markets midostaurin for treatment of AML.
Takeda	Direct payment for participation on data safety and monitoring board	11/11/2018	Direct COI. Takeda is developing TAK-650 for treatment of AML in phase III clinical trials.
AbbVie	Direct payment for consulting. This activity will end on 6/1/2019.	5/1/2019	Direct COI. Abbvie markets venetoclax for the treatment of AML in older adults.
Jazz Pharmaceuticals	Direct payment for consulting. This activity ended 12/31/2018	5/1/2019	Direct COI. Jazz Pharmaceuticals markets daunorubicin and cytarabine for treatment of AML

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Novartis	Direct payment for consulting. This activity ended 12/31/2018.	5/1/2019	Direct COI. Novartis markets midostaurin for treatment of AML.
Pfizer	Direct payment for consulting. This activity ended 12/31/2018.	5/1/2019	Direct COI. Pfizer markets glasdegib for treatment of AML in older adults for whom intensive chemotherapy is not an option.
Takeda	Direct payment for serving on a data safety and monitoring board.	5/1/2019	Direct COI. Takeda is developing pevonedistat in phase III clinical trials for treatment of AML.
Daiichi Sankyo	Direct payment for consulting. This activity ended on 4/30/2019	5/1/2019	Direct COI. Daiichi Sankyo is developing quizartinib in Phase III clinical trials for treatment of AML.
AbbVie	Direct payment for participation on a steering committee	2/5/2020	Direct COI. Abbvie is developing venetoclax in phase III clinical trials for treatment of AML in older adults.
Agios	Direct payment for participation on a steering committee	2/5/2020	Direct COI. Agios is developing AG-221 in phase III clinical trial for treatment of AML.
Janssen	Direct payment for participation on an advisory board. December 2019.	2/5/2020	Direct COI. Janssen markets decitabine for treatment of AML.
Takeda	Direct payment for participation on an advisory board. October 2019.	2/5/2020	Direct COI. Takeda is developing pevonedistat in phase III clinical trials for treatment of AML.

Other Notes

Dr. Stone specializes in hematological malignancies and related disorders, including AML. He has given multiple lectures and written extensively on AML therapy.